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Insulin-like growth factor-I (IGF-1) is a hormone associated with multiple 
physiologic outcomes including increased muscle growth and repair as well as 
uncontrolled cell growth, i.e. cancer.  Both exercise and nutritional status (in 
particular protein intake) have been observed to influence circulating IGF-1 
concentration but the magnitude and direction of effects have been inconsistent.  In 
addition, it was previously unknown if exercise modulated the effect of dietary protein 
on IGF-1 concentration or vice-versa.  This PhD research consisted of four studies 
designed to: 1) summarise past literature on exercise and IGF-1 concentration, 2) 
summarise previous research on dietary protein and IGF-1 concentration, 3) assess 
the acute response of exercise and/or dietary protein on IGF-1 concentration, and 4) 
investigate cross-sectional associations between physical activity, diet, and IGF-1 
concentration.   
To summarise previous literature, two systematic reviews and meta-analyses 
were performed.  The first focused on the association between total IGF-1 
concentration and dietary protein in healthy adults.  The intervention studies revealed 
increasing protein intake results in elevated total IGF-1 concentration (Cohen’s 
d=0.62; 95% CI -0.10 to 1.33). The cross-sectional studies demonstrated that, on 
average, total IGF-1 concentrations were 0.03 nmol/L higher for every 1 g/day 
increment in dietary protein (95% CI -0.01 to 0.07 nmol/L).  Despite high levels of 
heterogeneity (intervention I2=87.3%, cross-sectional I2=83.4%), consistency in the 
direction of effect suggests dietary protein is likely to increase total IGF-1.   
The second systematic review and meta-analysis focused on the association 
between total IGF-1 concentration and exercise in healthy adults. Based upon the 
acute total IGF-1 concentration response, the results indicated that endurance 
exercise tends to decrease total IGF-1 concentration (studies that compared pre- and 
post-exercise total IGF-1 concentration Cohen’s d= -0.55, 95% CI -0.86 to -0.23, I2 = 
74%; studies that compared to a non-exercise control Cohen’s d= -0.37, 95% CI -0.94 
to 0.20, I2= 80.4%).  Results of this meta-analysis also indicated that resistance 
exercise increases total IGF-1 concentration (studies that compared pre- and post-
exercise total IGF-1 concentration Cohen’s d= 0.21, 95% CI 0.09 to 0.34, I2= 53.6%; 
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studies that compared to a non-exercise control Cohen’s d= 0.65, 95% CI 0.23 to 1.06, 
I2= 87.3%).   
The acute effects of dietary protein and/or exercise on plasma free IGF-1 and 
the time-course thereof was investigated by conducting a three-way crossover 
intervention with 24 healthy participants (13 male).  The three conditions consisted 
of: 1) exercise (four 30 s sprints interspersed with 4 min 30 s of recovery- totalling 20 
min), 2) a high protein (42 g) meal and, 3) exercise immediately followed by a high 
protein meal.  In the non-exercising condition participants sat quietly for 20 min after 
consuming the high protein meal.  In every condition, participants provided 8 blood 
samples over the 5 h following the initial fasted, resting baseline blood draw.  
Additionally, a blood sample was taken 24 h after the initial baseline measure.  While 
there was no difference in the area under the free IGF-1 response curve between 
conditions, the shape of the response differed between conditions.  Specifically, free 
IGF-1 concentration was higher at 30 min (immediately after exercise) in the exercise 
condition without protein (p= 0.04) and in the protein condition without exercise, the 
24 h IGF-1 concentration was 17.5% higher (p= 0.02) than at baseline.  Free IGF-1 
concentration did not change over time, with respect to baseline, in response to 
exercise with protein.  
The cross-sectional relationships between dietary protein and total IGF-1 
concentration as well as physical activity and total IGF-1 concentration were 
investigated in 60,677 healthy adults enrolled in UK Biobank.  Every 1.0 g of dietary 
protein was associated with a 0.030 nmol/L increase in total IGF-1 concentration 
(95% CI 0.027 to 0.033; p< 0.001).  Individuals undertaking a moderate amount of 
physical activity (10-50 excess MET h/week) had 0.129 nmol/L greater total IGF-1 
concentration than participants completing a low amount of physical activity (less 
than 10 excess MET h/week) (95% CI 0.028 to 0.230).  Individuals in the high 
category of physical activity (>50 excess MET h/week) had a total IGF-1 concentration 
that was not significantly different from individuals in the low category of physical 
activity (<10 excess MET h/week) (-0.055 nmol/L; 95% CI -0.185 to 0.076).  When 
dietary protein and physical activity were included in the same model, physical 
activity did not change the relationship between dietary protein and total IGF-1 
concentration, nor vice versa.   
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The evidence presented in this PhD thesis is an overview of the associations 
between physical activity, dietary protein, and/or IGF-1 concentration, as opposed to 
a mechanistic analysis.  This overview can inform individuals seeking increased IGF-1 
concentration for the purpose of increased muscle mass, or for those wanting to lower 
IGF-1 concentration due to increased cancer risk.   The strength of the association 
between dietary protein and circulating total IGF-I concentration is stronger than that 
of physical activity and circulating total IGF-I concentration.  Thus, while our research 
has shown that dietary protein and resistance exercise increase both total and free 
IGF-1 concentration and endurance exercise decreases total IGF-1 concentration, the 
timeframe and dose(s) that exerts the most benefit has yet to be elucidated.  Future 
research may provide insight into measuring outcomes to determine how modifying 
dietary protein and/or physical activity, and thus IGF-1 concentration, influence 
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Insulin-like growth factor (IGF-1) is a hormone primarily secreted by the liver (1) .  
IGF-1 is similar in structure to insulin and regulates anabolic activity (1).  This 
hormone is important for increasing muscle growth and repair (1).  However, 
chronically elevated IGF-1 concentration can lead to uncontrolled cell growth.  IGF-1 
concentration may be modulated by environmental stimuli such as nutrition (2-4) and 
physical activity (5-10).     
Multiple studies with Drosophila have shown a low protein diet to be a determinant of 
lifespan (11-13).  Research on invertebrates has supported these findings, 
demonstrating that the ratio between protein to non-protein intake is an essential link 
between diet and longevity (11, 14).  Studies utilizing humans have confirmed the 
findings with Drosophila and invertebrates, revealing that a diet high in protein is 
linked to increases in cancer, diabetes, and overall mortality (15).    
How can a high protein diet be both beneficial and detrimental to our health at the 
same time?  In order to answer the question of why protein intake is beneficial for 
athletes (via increased muscle mass) but not for longevity we need to determine what 
differentiates athletes from the normal population.  The obvious answer to this 
question is exercise.  Athletes partake in a much higher quantity and intensity of 
exercise than the average individual.  Thus, does exercise somehow influence whether 
protein intake has a positive or negative effect?   It has been speculated that the key to 
this relationship is insulin-like growth factor-I (5-10).   
This PhD research sought to understand the associations between exercise and/or 
dietary protein and IGF-1 concentration through three aims: 1) systematically review 
the literature to investigate the relationships between dietary protein, exercise, and 
total IGF-1 concentration (serum and plasma); 2) investigate the effects of an acute 
bout of exercise and/or dietary protein on free plasma IGF-1 concentration; and 3) 
investigate cross-sectional associations between diet, and total serum IGF-1 
concentration, and how they may, or may not, be moderated by habitual physical 
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activity.   Four studies were performed to address the three aims.  The first study was 
a systematic review and meta-analysis that investigated the relationship between 
dietary protein and total IGF-1 concentration (serum and plasma) (chapter 3).  The 
second study was a systematic review and meta-analysis exploring the relationship 
between exercise and total IGF-1 concentration (serum and plasma) (chapter 4).  The 
third study was an intervention study analysing the effects of an acute bout of exercise 
and/or dietary protein on free plasma IGF-1 concentration (Exercise, Dietary Protein, 
and Combined Effect on IGF-1) (chapter 5).  The fourth study is a population-based, 
longitudinal study utilizing data from the UK Biobank survey to investigate 
associations and possible interactions between physical activity, diet, and total serum 













2. LITERATURE REVIEW 
 
2.1 IGF-1  
IGF-1 was first identified in 1956 (16).  It was first named “sulphation factor” due to 
its ability to stimulate 35-sulphast into rat cartilage.  In 1972 the denotation 
“sulphation factor” was replaced with the term “somatomedin” to convey growth 
hormone’s control over the substance and its mediating effects (based on the 
somatomedin hypothesis) (16, 17).  In 1976 IGF-1 was isolated from human serum 
(18, 19).  The structural similarities of IGF-1 to proinsulin led to it being yet again 
renamed as “insulin-like growth factor 1”(19).   
IGF-1 is a peptide with 70 amino acids and a molecular weight of 7649 Da.  It consists 
of an A chain, B chain, and C peptide region. The A and B chains are connected by 
disulphide bonds while the peptide region is composed of 12 amino acids (19).   
IGF-1 is similar to insulin in structure.  This similarity is due to the fact that proinsulin 
and IGF-1 evolved from the same precursor molecule 60 million years ago (8).  Over 
time the pituitary gland formed, growth hormone appeared, and IGF-1 diverged from 
insulin (8).  As IGF-1 and insulin took on different evolutionary roles they developed 
affinities for different receptors (8).   
IGF-1 varies through the life cycle.  From birth to puberty circulating IGF-1 increases 
in order to assist in growth (20).  After puberty IGF-1 is relatively stable through mid-
life.  Later in life, serum IGF-1 begins its decline in response to lower growth hormone 
levels (20). The older adults have a reduced growth hormone secretory burst 
frequency, a shorter half-life of endogenous growth hormone, and a lower daily 
growth hormone secretory rate than their younger counterparts (21).  Since IGF-1 is 
modulated, in part, by growth hormone.  Decreases in growth hormone secretory 
patterns contribute to the decline of IGF-1.   
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IGF-1 is produced by numerous tissues.  The site of secretion has been shown to 
determine the actions of IGF-1 (19).  The majority of IGF-1 is secreted by the liver, 
after which it functions as an endocrine hormone and is transported to other tissues 
(19, 22).  Skeletal muscle, stimulated via muscular contraction, can also secrete IGF-1, 
where IGF-1 acts locally in both an autocrine and paracrine fashion (23).  
Cartilagenous cells secrete IGF-1, where it acts locally as a paracrine hormone (19, 
24).  When IGF-1 acts in an autocrine mode it can function as an oncogene (19, 25).  
There are a few different ways that IGF-1 can be measured: as total IGF-1 or free IGF-
1, in serum or plasma and IGF-1 mRNA are just a few examples.  Serum measures of 
IGF-1 are highly correlated with plasma measures (r=0.92) with serum measuring 
approximately 11% higher than plasma IGF-1 (26).  A measurement of total IGF-1 
includes the total extractable amount of IGF-1 (a combination of unbound IGF-1 as 
well as the IGF-1 that is bound to IGFBPs).  However, due to a variation in insulin-like 
growth factor binding proteins (IGFBPs) a total IGF-1 sample is not necessarily 
representative of biologically active IGF-1 (27).  The amount of biologically active IGF-
1 is termed free IGF-1, and represents the circulating IGF-1 that is not bound to a 
binding protein or receptor.  It should be noted that a measure of total IGF-1 is not 
able to be representative of IGF-1 production, as it is unable to measure any IGF-1 that 
is bound to target tissue receptors.  A normal median serum total IGF-1 concentration 
for adults aged 35 to 39 y is 23.58 nmol/L (22.73 nmol/L for males and 24.37 nmol/L 
for females) (28).   The free IGF-1 is a measure of the IGF-1 that is biologically active 
and available to find to receptors in particular tissues.  Normal mean free IGF-1 
concentration for adults aged 35 to 45 y is 0.16 nmol/L for males and 0.16 nmol/L for 
females (29).  In order to further understand the relationship between bound and free 
IGF-1, more detail regarding IGFBPs will be described.   
2.1.1 IGF Binding Proteins 
There are six IGF binding proteins, IGFBP1-6, all of which are produced by the liver.  
All six binding proteins are structurally similar, sharing 50 percent homology, and 
bind with the insulin-like growth factors.  The binding proteins have four primary 
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functions: 1) to regulate the efflux of IGFs from vascular space by serving as transport 
proteins, 2) to modulate the metabolic clearance of IGFs by binding and prolonging 
the half-lives of the IGFs, 3) to assist in localization to specific tissue and cell types, 4) 
to regulate binding between the IGFs and their receptors.   IGFBP-1 and IGFBP-4 
downregulate IGF-1 (30).  IGFBP-1 is inhibited by growth hormone.  The inhibition of 
IGFBP-1 releases IGF-1 and simulates both the MAPK-ERK pathway and the PI3K-TOR 
pathway.  IGFBP-1 is inhibited by TOR and amino acid availability (30-32).  Thus, 
when IGFBP-1 is at its lowest, IGF-1 availability is at its highest (30).  IGFBP-2 
functions under autocrine control and modulates adipocyte self-regulation (33).  
IGFBP-3 assists with IGF-1 stability (30).  IGFBP-5 inhibits the activity of IGF-1 by 
binding and inhibiting the interaction of IGF-1 with a type I receptor (34).  IGFBP-6 
differs from the other binding proteins in that it has the lowest affinity for IGF-1 and 
the highest affinity for IGF-2 (35). 
 
IGFBP-3 is the most abundant binding protein.  Approximately 75 percent of IGF-1 in 
circulation is bound to IGFBP-3, making IGFBP-3 the main transport protein for IGF-1 
(36, 37).  IGFBP-3 is primarily regulated by growth hormone but it is also regulated to 
some extent by IGF-1 (19).  Since both IGFBP-3 and IGF-1 are primarily regulated by 
growth hormone their secretion patterns are similar (38).  
The primary functions of IGFBP-3 include: prolonging the half-life of IGF-1, 
modulating growth promoting effects, and modifying interactions of IGF-1 with cell 
surface receptors (39).  The complex roles of IGFBP-3 are not yet fully understood.  
Current research is investigating the possibility of IGFBP-3 as a prognostic tumour 
marker (38).   
The complex created as a result of IGF-1 and IGFBP-3 binding also includes one 
molecule of a protein named acid labile subunit (ALS) (19).  In the form of a tertiary 
complex it can circulate in the plasma, prolong the half-life of IGF-1, and alter 
interaction with cell receptors.  Non-bound IGFBP-3 has a half-life of 30-90 minutes 
(38).  Non-bound IGF-1 has a half-life of 10 minutes (38).  When bound in their 
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tertiary complex their half-life is extended to 12 hours (38).  The large size of the 
complex hinders it from crossing the capillary barrier (40, 41).      
2.1.2 IGF-1, Cell Replication, and Cancer 
The association between IGF-1 and cancer begins with cell division.  An increase in 
free IGF-1 leads to increases in cell proliferation via the TOR pathway (described in 
section 2.1.3) (42, 43).  The increase in free IGF-1, and subsequent activation of the 
TOR pathway, also decreases apoptosis.  Thus, with each cell division comes an 
accompanied decrease in telomere length and increased risk of DNA mutation (42-
44).  Telomere shortening is associated with aging, cancer, and eventually increased 
mortality (45).  Furthermore, it has been speculated that cancerous cells, over time, 
develop the ability to produce their own supply of IGF-1 (46).  This allows cancerous 
cells to signal themselves, or nearby cells, via an autocrine or paracrine method (46).  
In this way, cells increase their replication rate and increase the risk of mutation. 
The measurement of both IGFBP-3 and IGF-1 can provide additional insight into cell 
replication and cancer risk.  A high circulating IGF-1 concentration is associated with 
an increased risk of cancer (47).  However, a high IGFBP-3 concentration is associated 
with a decreased cancer risk (47).   Additional research is needed before making 
diagnoses based solely off of the IGF-1: IGFBP-3 ratio.     
2.1.3 Phosphoinositide 3-Kinase Pathway 
Phosphoinositide 3-kinase pathway (PI3K) and the MAPK/ERK pathway regulate the 
anabolic processes of protein synthesis and growth (30, 48).  Growth is largely 
mediated by the mechanistic target of rapamycin [mTOR] pathway (30).  Stress 
resistance, which is significant for aging, is modulated by forkhead transcription 
factors [FOXOs] (49).  Since mTOR and FOXO are on opposing sides of the PI3K 
pathway they reflect antagonistic pathways that modulate physiological processes.  
The early sleep phase is controlled primarily by the GH-IGF-1-mTOR pathway.  Late 
sleep, however, is dominated by the FOXO pathway.   
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Growth factors, including IGF-1 and insulin, signal via the PI3K pathway.  This 
pathway modulates energy, redox, and aspects of aging (50, 51).  PI3K is associated 
with NAD(P)H oxidase [NOX] activation (50).  This obstructs tyrosine phosphatases 
via oxidative modification of redox-regulated cysteine residues.  The mutation or 
downregulation of elements in the PI3K pathway that promote the FOXO pathway and 
hinder the mTOR pathway has been shown to slow the aging process and prolong 
lifespan (52).  The junction at which a signal is directed either towards the mTOR or 
FOXO pathway is modulated by protein kinase B (PKM/Akt).  Phosphorylation and 
activation of Akt signals the mTOR pathway and inhibits the FOXO pathway.  If Akt 
phosphorylation does not occur then the FOXO pathway is activated.  There are three 
different Akt isoforms, each of which serve a slightly different function.  The Akt1 
isoform has the broadest distribution and is involved in the processes of growth, 
protein and glycogen synthesis, immunity, and aging.  Its functions are primarily for 
the mTOR pathway.  The Akt2 isoform regulates glucose and fat deposition (53, 54).  
Akt3 is also present in the testes and the brain.  These pathways are mutually 
exclusive so when the mTOR pathway is activated, the FOXO pathway is inhibited and 
visa-versa.   
IGF-1 is thought to primarily signal the PI3K pathway during early sleep.  At this time 
IGF-1 release is independent of insulin.  IGF-1 may also increase during meal cycles, 
like insulin, but that is not thought to be the time point in which IGF-1 signalling 
predominantly functions.  Both the MAPK/ERK and PI3K pathways converge on 
mTOR which critically mediates GH-IGF-1 regulation of protein synthesis, cell growth, 
and cell proliferation (including that of cancers). 
The PI3K pathway can also work in cooperation with the MAPK/ERK pathway to 
modulate IGF-1 signalling (55).  This is primarily observed during sleep (55).  ERK 
protein levels have been shown to peak during the early sleep/rest period and be low 
during the waking period, in mice (56).  During early sleep IGF-1 availability is 
greatest.  During this time IGF-1-Akt signalling activates the mTOR pathway via the 
tuberous sclerosis protein 2 [TSC2] (57).  This causes IGF-1 and mTOR to both 
stimulate cell proliferation and inhibit cell death (57).   
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 2.1.4 Mechanisms Explaining the Association between Physical 
Activity and IGF-1  
There are three leading theories as to how the IGF pathway is involved in increased 
muscle mass and resistance exercise (58, 59): 1) exercise increases growth hormone 
secretion, which results in increased hepatic production of IGF-1 and circulating IGF-1 
(60, 61); 2) growth hormone secretion, stimulated by exercise, induces endogenous 
production of IGF-1 by the muscle which can cause an increase in muscle mass via an 
autocrine method (62, 63); and 3) muscular contractions stimulate the muscle to 
produce IGF-1 independently of circulating growth hormone (64).  
The first theory focuses on IGF-1’s insulin-like properties, specifically metabolic and 
anabolic properties.  The second model involves endogenous muscle production of 
IGF-1 and autocrine signalling.  The third, and most recently discovered, influences 
injury repair and possibly mechanisms involved with increased muscle mass.  When a 
myofibril is injured a myofibre dies, leaving basal lamina and satellite cells as the site 
of injury.  The death of the myofibre triggers satellite cells to begin the regeneration 
process (59, 65-69).  The satellite cells undergo at least one mitotic cycle, after which 
some of them differentiate into myoblast-like cells (59, 66, 70-72).  These new 
myoblasts can serve to help the injured myofibre in one of two ways: 1) the myoblasts 
can fuse with each other to form new fibres or 2) the myoblasts can join the surviving 
myofibres of the damaged tissue (59, 66, 73-75).  IGF-1 may play a role in this repair 
process due to its presence in the cytoplasm of myoblasts, myotubes, and satellite 
cells during the regeneration process (59, 76, 77).  This theory was confirmed by a 
study that showed a decrease in the quantity and magnitude of regenerating 
myofibres when an antibody was used to neutralize IGF-1 activity (59, 78).  Although 
further work needs to be conducted in this area it appears that IGF-1 may be an 
important factor in the muscle regeneration process.   
The same process that makes IGF-1 useful for muscle regeneration may also aid in 
increasing muscle mass due to increased loading.  An increase in load initiates the 
same autocrine/paracrine satellite cell-derived myoblasts as previously described in 
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muscle repair.  The myoblasts then fuse with existing myofibres (59, 79-83).  This 
fusion provides additional myonuclei to the muscle, indicating  an increase in muscle 
mass (59, 82, 84-88).  In addition, an increase in load and/or stretch can stimulate 
mechanogrowth factor (MGF), an IGF-1 isoform (59).  MGF aids in the anabolic 
process by activating muscular satellite cells in the same method as IGF-1 (89). 
There are three main theories behind the correlation between exercise training level 
and circulating IGF-1.  The first theory has been observed in cross-sectional studies 
and indicates a positive correlation between fitness and IGF-1 concentration (90, 91).   
The second theory is supported by prospective studies that have found that increased 
training decreases circulating IGF-1 (91-94).  It should be noted that the prospective 
studies were of relatively short duration (three days to five weeks), which only 
allowed them to see the short-term response of IGF-1.   
The third theory is a combination of the aforementioned two.  It proposes that the 
IGF-1 response to exercise is bi-phasic,  that is an initial catabolic-type response of a 
decrease in IGF-1, followed by a more chronic anabolic response of increased IGF-1 in 
response to prolonged training (over five to six weeks) (92, 95).  This model is 
supported by Rosendal et al. when they conducted a chronic (11 week) training study 
on a group of untrained and a group of trained participants (95).  They found total 
IGF-1 decreased in both groups after the initial  four weeks of training (95).  This 
finding is supported by multiple studies analysing endurance-type exercise (91-93, 
96).  When Rosendal et al. measured the tissue thickness surrounding the Achilles 
tendon they showed a degradation of type I collagen after four weeks of training, 
followed by a net synthesis of collagen after the entire 11 weeks of training were 
completed (95).  It would be reasonable to extrapolate these finds to a systemic 
application, which would support the bi-phasic theory of IGF-1 response to exercise 
(97).  More extensive changes were observed in the untrained participants compared 
to the trained participants.   
A promising study was conducted utilizing professional cyclists and the authors 
proposed a possible mechanism to explain the third concept mentioned above  (96).  
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They studied these cyclists over the course of a three-week cycle tour, thus a very 
well-trained group, and found an acute increase in circulating IGF-1 levels.  They 
theorized that this increase was due to short-term responses to the high demands of 
the tour race.  At the end of the three weeks, however, the athlete’s free IGF-1 
decreased to become lower than at baseline, prior to the race, while the total IGF-1 did 
not change.  Their proposed mechanism revolves around a greater demand for IGF-1 
in the tissue of the active muscles during the first several days.  This would also cause 
any IGF-1 produced by the liver to be promptly taken by tissues in order to keep 
systemic circulation stable (96).   
 2.1.5 Mechanism Explaining the Association between Dietary Protein 
and IGF-1 
During overall caloric restriction, serum IGF-1 is decreased due to a reduction in 
growth hormone receptors (6).  Studies conducted on rats have shown that steady-
state, hepatic IGF-1 mRNA levels are lower in fasted rats than in their well-fed 
counterparts (6, 98).  This suggests that the decrease in circulating IGF-1 
concentration may be due to decreased production caused by decreased transcription 
of IGF-1 mRNA (6, 98).  This mechanism is further supported by research in which a 
reduction in IGF-1 mRNA concentration was observed in the fasted state accompanied 
by a reduction in the rate of IGF-1 gene transcription (6, 99).  When refed, steady-state 
mRNA transcription increased (6, 99). 
A reduction in protein intake decreases circulating IGF-1 concentration via the 
previously described mTOR or FOXO pathways.  Due to their opposing functions, 
mTOR for growth and FOXO for stress resistance, diets low in protein or energy will 
activate the FOXO pathway.  In this way stress resistance and longevity are promoted.  
A reduction in dietary protein intake can also decrease circulating IGF-1 concentration 
by a different mechanism (6).  A decrease in protein intake leads to post-receptor 
resistance to the action of growth hormone (100).  Thus, reduced growth hormone 
binding does not mediate IGF-1 concentration (101).  Reduced protein intake 
decreases hepatic IGF-1 mRNA in proportion to the decline in serum IGF-1 (101).  
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Therefore, it can be deduced that alterations in serum IGF-1 are partially determined 
by transcriptional events (6).   
2.2 Dietary Protein and IGF-1 
An association between IGF-1 and nutrition was first demonstrated in 1973 when 
children with protein-calorie malnutrition were observed to have low levels of IGF-1, 
even though their growth hormone concentrations were high (6, 7).  This finding was 
supported by research in which participants fasted for three days and yet no change 
in serum IGF-1 concentration was observed, despite having been given growth 
hormone injections (6, 102).       
In the countless studies conducted since 1973 it has been repeatedly shown that IGF-1 
plasma levels are regulated predominantly by nutrient intake (8).  Both total caloric 
intake as well as protein intake can modulate IGF-1 concentration.  A reduction in 
caloric intake by 50% will produce a significant decrease in IGF-1 (8, 9).  This 
reduction is due to a decrease in IGF-1 gene transcription.  A reduction of protein 
intake as small as 25% will produce an equivalent decrease in IGF-1 by regulating 
mRNA stability and translation (8).  
In rats placed on a diet low in protein, serum IGF-1 is observed to be decreased, but 
only small decreases in growth hormone binding are observed (103).  When rats on a 
low protein diet are treated with growth hormone, the IGF-1 response is significantly 
decreased (10).  This shows that a decrease in protein intake leads to post-receptor 
resistance to the action of growth hormone, as described in section 2.1.5 above.   
In order to determine how graded protein intake influences serum IGF-1 a study was 
conducted in which participants fasted for five days then were refed for five days.  The 
refeeding consisted of one of three different diets with varying amounts of protein and 
calories.  The five days of fasting caused a 67 percent decline in IGF-1 (5).  One group 
then received 35 kcal and 1 g of protein per kg ideal body weight.  This increased their 
serum IGF-1 to over 70 percent of control values.  Another group received a protein-
deficient (40 percent RDI), but kcal-sufficient, diet.  Their serum IGF-1 increased to 55 
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percent of control (5).  A third group consumed a diet that was both kcal and protein 
restricted.  Their serum IGF-1 values continued to decline over the five days of 
refeeding.  This study demonstrated that a diet sufficient in calories but deficient in 
protein is not as effective in restoring IGF-1 levels as a diet with higher protein intake.  
Thus, showing that protein, and not just energy, is a key moderator of IGF-1 levels.  
The next step after determining that protein influenced IGF-1 levels was to determine 
the dose effect of protein on IGF-1.  A study was conducted in which they 
administered differing levels of protein after fasting to determine how much protein 
was needed to adequately restore IGF-1 levels (104).  Protein intakes of 0.2 g/kg IBW, 
0.4 g/kg IBW and 1 g/kg IBW were consumed.  They found a dose effect in which 
every increase in protein resulted in increased serum IGF-1 values.  Only the 1 g/kg 
IBW dose was large enough to effectively normalize serum IGF-1 values (104).  This 
was the study’s largest dose so we are unable to draw any conclusions about a 
saturation point.  If a larger dose would have been administered it is possible that a 
saturation point would exist in which an increase in protein does not elicit any greater 
IGF-1 response.  
While this section provides an overview of the history of research on dietary protein 
and IGF-1, more specific details regarding adult human participants, not in negative 
energy balance, are provided in Chapter 3 via a systematic review and meta-analysis.  
The systematic review and meta-analysis expand upon this section in order to provide 
a quantitative estimate of the effect that dietary protein has on IGF-1 concentration in 
healthy adults.    
2.3 Physical Activity and IGF-1 
2.3.1 Exercise Type 
2.3.1.1 Acute effect of exercise 
There are indications that exercise can acutely and chronically impact IGF-1.  The 
following studies (summarised in Table 1) demonstrate how exercise influences the 
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IGF-1 response: throughout resistance training exercise, between different resistance 
training designs, and between different swimming periodisation phases.  The 
systematic review and meta-analysis presented in Chapter 4 provides specific details 
on all research published before December 13, 2019 in which the acute effect of a 
single bout of exercise on total IGF-1 concentration in healthy adults was evaluated.  
A study by McCall et al. analysed the influence of a resistance training protocol 
designed to increase muscle mass on the IGF-1 response.  Eleven men between the 
ages of 18 and 25 chose to participate in the study (105).  All participants had 
recreational resistance training experience.  The study lasted 12 weeks and consisted 
of training three days per week.  The programme design was intended to increase 
muscle mass with eight exercises, three sets at 10 RM with one-minute rest between 
both sets and exercises.  Four exercises utilised the biceps brachii and four exercises 
used major muscle groups of the whole body.  Acute measurements were taken at 
week three and week eight of the study at time points pre-exercise, mid-exercise 
(after four out of the eight exercises were completed), and ten minutes after exercise.  
At week three the mid-exercise and post-exercise IGF-1 measurements were 
significantly greater than the pre-exercise measurement.  At week eight the mid-
exercise measurement was significantly greater than the pre-exercise measurement.  
In addition, post-exercise IGF-1 was significantly less than mid-exercise.   
A study analysing the acute results of different resistance training designs on serum 
IGF-1 utilised nine male participants at 24 +/- 4 years old (106).  Specifically, this 
study evaluated different training programme designs in order to identify potential 
differences in the IGF-1 response for training schemes that fluctuated: intended 
training adaptation, weight, and rest period.  Participants performed six different 
exercises protocols in a random order.  Each different exercise protocol took place 
over one day and all training sessions used the same eight exercises.  The resistance 
training programmes were named according to their intended goal, load, and rest with 
“S” indicating a programme designed for strength and “H” denoting a programme 
designed for hypertrophy.  For example, one training session has the nomenclature 
“S5/1”, this programme would be designed for strength and consist of a weight 
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equivalent to a 5RM with 1 minute of rest between sets and exercises.  Thus, the 
programmes used in this study were developed to systematically vary load, rest 
period, and intended training goal in order to analyse the influence of these three 
factors on the acute IGF-1 response.  The following protocols were performed by the 
participants: S5/1, S5/3, S10/3, H5/1, H10/1, H10/3.  Serum IGF-1 concentration was 
measured pre-exercise, mid-exercise (after four of eight exercises), as well as 0, 5, 15, 
30, 60, 90, and 120 minutes post-exercise.  The results showed that the S5/3 protocol 
produced a significant increase from pre-exercise at 0- and 5-minutes post-exercise.  
The S10/3 protocol resulted in a significant increase in IGF-1 at 30- and 90-minutes 
post-exercise.  The H10/1 programme showed a significant increase at 90 minutes 
post-exercise.  The H5/1 programme elicited a significant increase in IGF-1 at mid-
exercise and 5 minutes post-exercise.  While the results of this study may seem varied 
the main conclusion can be in the fact that IGF-1 concentration increased after two of 
the three strength training protocols and two of the three hypertrophy programmes.  
The results of all programmes showed either an increase or no change during and 
following exercise.   
A study by Filho et al. investigated the effect of swimming periodisation phase on IGF-
1 concentration in younger participants (ages 16-19 years) (107).  Nine male trained 
swimmers performed coach prescribed swimming workouts over the course of 19 
weeks.  Pre- and post-exercise serum IGF-1 and IGFBP-3 measurements were taken 
during a standard day of training in the extensive, intensive, and tapering phases.  In 
this way the pre- and post-exercise measures could be compared over time to analyse 
the effects of different training phases.  The acute results showed no significant 
change in IGF-1 from pre to post-exercise measurements during the extensive phase.  
A reduction of serum IGF-1 from pre to post-exercise measurements was observed 
during the intensive stage of training.  No significant difference between pre- and 
post-exercise IGF-1 was observed in the tapering phase.   
The inconsistent results observed when analysing the acute effects of exercise training 
may have occurred for a variety of reasons.  A possible reason for the inconsistency in 
resistance training acute measures could be due to the order of the exercises.  It is 
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possible that in the beginning of training, week three, all exercises represented a new 
stimulus and elicited an IGF-1 response.  However, further into the training 
programme, it is possible that the intensity of the first four exercises differed from the 
last four exercises, eliciting a different response.   In addition, small sample size and 
the fact that each exercise programme was only performed once may have influenced 
the results of Kraemer et al.’s study (106).  The change in periodisation phase, and 
thus volume and/or intensity, may have produced the inconsistent results observed in 
Filho et al.’s study (107).  The reduction in IGF-1 observed during the intensive phase 
would indicate catabolism via inhibition of the mTOR pathway.  In contrast the 
increase in IGF-1 observed via an increase in the tapering phase would suggest an 
anabolic pathway and activation of the mTOR pathway.  Table one shows a few 
representative studies that reflect the effect of a variety of different modes and 
intensities of exercise on the IGF-1 response.   
2.3.1.2 Chronic effect of exercise 
Several studies measured the result of chronic resistance training designed to 
increase muscle mass on serum IGF-1 in untrained males and females.  One study 
compared the effect of single-set and multiple-set programmes against a non-
exercising control group in order to compare their effects on serum IGF-1 (58).  The 
participants were 31 males and females 25-50 years old.  They trained three days a 
week for 25 weeks.  Training consisted of whole-body exercises performed at 8-12 
repetition maximum. The first group performed a single repetition of a circuit 
consisting of torso flexion, leg extension, leg curl, chest press, seated row, tricep 
extension, and bicep curls.  The second group repeated the same circuit three times.  
The third group was a non-exercising control.  Resting serum IGF-1 and IGFBP-3 
measurements were taken before training at baseline, 13 weeks, and 25 weeks.  
Results were analysed to investigate any influence of time or single vs multiple-set 
exercises on IGF-1 and IGFBP-3.  Resistance exercise was found to increase IGF-1 
concentration between baseline and 13 weeks, with the single set group increasing 
20.5% from baseline and the multiple set group increasing from 18% from baseline.  
This elevated level of IGF-1 concentration was maintained for both groups between 13 
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and 25 weeks.  Only multiple sets of resistance training was found to reduce IGFBP-3 
by 20% between weeks 13 and 25.  The relative intensity of training was maintained 
throughout the 25 weeks, through regular adjustment of weight loads therefore the 
lack of change later in the study cannot be attributed to adaptation to the training 
stimulus.  The results of this study support the proposed bi-phasic adaptation to 
exercise previously described (Section 2.1.4).  Moreover, an interesting finding of this 
study is the fact that the multi-set group exhibited a decrease in IGFBP-3 in the second 
half of the study.  This decrease in IGFBP-3 allowed a greater concentration of free 
IGF-1 in circulation because there was a lesser amount of binding protein to which it 
could attach.  The greater concentration of free IGF-1 may have contributed to the 
increases in strength. 
A study by McCall et al. (summarised in Section 2.3.1.1) investigated the result of 
chronic resistance training for increased muscle mass on serum IGF-1 utilised 
untrained males.  This research compared the effect of three elbow flexor exercises to 
the same three elbow flexor exercises plus an additional six exercises that involved 
major muscle groups (108).  The repetitions performed were adjusted over time: 
weeks zero to three used three sets of 10-12 reps, weeks four to six used four sets of 
eight to ten reps, weeks seven to ten used four sets of six to eight reps.  Resting serum 
IGF-1 concentration was collected at baseline before exercise and after ten weeks.  No 
significant change in IGF-1 was observed for either the elbow flexor only group or the 
elbow flexor plus major muscle group.   
A third study was conducted to also analyse the influence of a resistance training 
hypertrophy protocol on the IGF-1 response.  Eleven men between the ages of 18 and 
25 chose to participate in the study (105).  All participants had recreational resistance 
training experience.  The study lasted 12 weeks and consisted of training three days 
per week.  The programme design was that of muscle hypertrophy with eight 
exercises, three sets at ten RM with one-minute rest between both sets and exercises.  
Four exercises utilized the biceps brachii and four exercises used major muscle 
groups of the whole body.  Resting serum IGF-1 concentration was measured before 
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exercise at baseline and at 12 weeks.  No significant changes were observed in the 
resting measurements at baseline and 12 weeks.   
A study investigating the effects of a power and strength programme on both older 
and younger men was conducted to see whether a programme with daily undulating 
periodization had an effect on chronic changes in IGF-1 serum measurements (109).  
Eight men with a mean age of 30 years were included in the younger age group and 
the older age group included nine men with a mean age of 62 years.  The resistance 
programme was ten weeks long and consisted of training three days per week.  All 
three days of training included the same ten exercises.  The first day of resistance 
training incorporated weight that was three to five RM with two to three minutes of 
rest between sets and reps.  The second day of training included eight to ten RM with 
one minute of rest between each set and rep.  The third day of training each week 
consisted of a weight that was 12 to 15 RM but the participants only performed six to 
eight reps in order to focus on explosive power.  They rested one to two minutes 
between sets and repetitions.  Serum IGF-1 measurements were taken in a rested 
state at baseline and at ten weeks.  No significant change was observed in IGF-1 for 
neither the young nor the older group over the course of the ten weeks.   
All of the aforementioned studies analysed the chronic effects of resistance training on 
the IGF-1 response.  One study showed an initial increase in IGF-1, followed by 
maintenance of this elevated IGF-1 level, but a decrease in IGFBP-3 in the latter half of 
the study (58).  The other three studies showed no significant change in IGF-1 
concentration over time (105, 108, 109). This lack of change could be attributed to 
insufficient power due to a low sample size in some of the studies or changes in 
duration of intervention (number of training days per week as well as length of entire 
programme).  If Borst et al.’s study used a greater intensity it may have signalled more 
satellite cell-derived myoblasts, subsequently requiring a greater amount of IGF-1 
and, thus, a larger IGF-1 response.  It is possible that the change in study duration 
compounded with changes in training days per week did not allow for enough 
exposure to the stimulus of exercise in order to produce a significant IGF-1 response 
in some studies (105, 108, 109).     
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A single study investigated the effect of swimming training in younger participants 
(ages 16-19 years) over the course of 19 weeks (107).  This study, by Filho et al., was 
previously described (Section 2.3.1.1).   Serum IGF-1 and IGFBP-3 measurements 
were taken before and after exercise during a standard day of training in the 
extensive, intensive, and tapering phases.  In this way the pre- and post-exercise 
measures could be compared over time to analyse the chronic effect across different 
training cycles.  The only chronic change in serum IGF-1 was observed between the 
intensive and tapering phases.  Post-exercise IGF-1 was significantly greater in the 
tapering phase than in the intensive training phase. Post-exercise IGFBP-3 was 
significantly lower in the post-training measurements of the intensive phase when 
compared to the tapering phase.  The results of this study also point toward a biphasic 
trend in IGF-1 throughout the swimming season, supporting the theory of a bi-phasic 
mechanism in trained athletes previously described.  The reduction in IGF-1 observed 
during the intensive phase would indicate catabolism via inhibition of the mTOR 
pathway.  In contrast. the increase in IGF-1 observed in the tapering phase would 
suggest an anabolic pathway and activation of the mTOR pathway.  The decrease in 
IGFBP-3 during the intensive phase and increase during the tapering phase is the 
opposite of what was observed in the previously mentioned  study by Borst et al. (58).  
The explanation for the differences in these findings could be due to the different 
types of training.  Borst et al. used resistance training exercises designed to elicit a 
hypertrophic response, whereas this study used swim training.   
A single study has investigated the effect of a multimodal training programme in 
highly active participants (>30 minutes of structured exercise at least four days per 
week) (110).  The multi-modal training approach included resistance training, 
interval sprints, yoga, and endurance running all performed within a week.  This 
allowed the researchers to observe the effects of multiple different exercises on the 
serum IGF-1 response.  Sixty-three males between the 25 and 55 years of age 
performed the twelve-week study.  The first day of training each week consisted of a 
60-minute resistance training session designed to elicit increases in muscle mass.  
Specifically, participants completed a dynamic warm-up, footwork, agility, lower and 
upper body resistance, and core exercises that were all performed for two to three 
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sets weighted to induce failure between 10-15 repetitions.  Rest periods were 30 
seconds between sets and 60 seconds between exercises.  The second day of training 
consisted of interval sprints, which took place over a time period of 35 minutes and 
included either seven sets of 30 second, maximum effort, sprints with four minutes of 
recovery or ten sets of 60 seconds, moderate effort, sprints with two minutes of rest.  
The third day of training was 60 minutes of either yoga, stretching, or Pilates.  The 
fourth day of training each week was an endurance exercise consisting of 60 minutes 
at 60 percent maximal effort in any mode of exercise (running, cycling, swimming, 
rowing, etc).  Resting serum IGF-1 concentration was measured at baseline and after 
twelve weeks.  The results showed no significant change in the serum IGF-1 from 
baseline to twelve weeks.  There are a few reasons why this study did not observe 
significant changes in IGF-1.  The first reason being that the participants were all 
highly active, so a protocol with only four days of training at 60 percent or less of their 
maximum might not have elicited sufficient strain.  Depending upon the individual 
this might have even been a decrease in activity level from that which they were 
accustomed.  In addition, the programme resulted in significant within-group 
variation of training.  For example, the choice of sprint programmes, and the choice of 
Pilates vs stretching vs yoga, and the choice of mode of exercise for endurance 
training induced a large amount of variation in the training programme.  Perhaps they 




































3days/wk. G1: single 
set, G2: multiple-set, 
G3: nonexercising 
control. Whole body 
exercises 8-12 reps 




at 0 weeks, 
13 weeks, 
and 25 weeks 
(completion) 
None G1: IGF-1 increased by 
20.5% at week 13, no 
change from week 13-25. 
IGFBP-3 no change. G2: 
IGF-1 increased by 18.5% 
at week 13, no change 
from week 13-25. IGFBP-3 















2days/wk. G1: elbow 
flexor 3 exercises. G2: 
whole body= 3 elbow 
flex + 6 major muscle 
groups.  Protocol for 
all groups: weeks 0-3: 
3 sets x 10-12 reps, 
weeks 4-6: 4 sets x 8-
10 reps, weeks 7-10: 
4 sets x 6-8 reps. 
Weight to failure. 
Plasma IGF-1 
at 0 weeks 
and 10 weeks 
(completion) 
None No significant change in 
IGF-1. 


















3days/wk.  Daily 
undulating 
periodization with 10 
exercises. Day 1: 3-5 
RM with 2-3 min rest. 
Day 2: 8-10 RM with 1 
min rest. Day 3: 12-15 
RM performing 6-8 
reps for explosive 
power and 1-2 min 
rest between sets. 
Serum IGF-1 
at 0 weeks 
and 10 weeks 
(completion) 
None No significant change in 
IGF-1 for either young or 
old.  No IGF-1 

































4days/wk. Day 1: 
resistance. Day 2: 
interval. Day 3: yoga. 
Day 4: endurance. 
Serum IGF-1 
at 0 weeks 
and 12 weeks 
(completion) 
None No significant change in 
IGF-1. 





















3days/wk. 3 x 10 RM 
sets for 8 exercises 
with 1 min rest 
between sets and 
exercises. 4 exercises 
for biceps brachii and 
4 for major muscle 
groups of whole body. 
Serum IGF-1 
resting at 0 







exercise at 4 
weeks and 8 
weeks. 

















No significant change in 
IGF-1 from 0-12 weeks.  
Kraeme




















6 protocols, same 8 
exercises in all 
protocols. S-series use 
3-5 sets, H-series use 
3 sets. S5/3: 5RM 
with 3 min rest 
between sets and 
reps. S5/1: 5RM with 





(after 4 of 8 
exercises), 
and 0, 5, 15, 




IGF-1 at 0- and 
5-min post-
exercise. S10/3: 
sig increase at 




10RM with 3 min rest. 
H10/1: 10RM with 1 
min rest. H5/1: 5RM 
with 1 min rest. 
H10/3: 10RM with 3 
min rest. 




increase at 90 
min post-
exercise. H5/1: 







































phase: no change 
in IGF-1. 
No change in 




exercise decreases in IGF-
1 when compared to 
tapering phase (39.0+/-
4.7 and 47.0+/-12.3 
nmol/L). 
Intensive phase: decrease 
in post-training IGFBP-3 
compared to tapering 




Section 2.4 Dietary Protein, Physical Activity and IGF-1 
The exact relationship between protein intake, IGF-1 and exercise has yet to be 
determined.  While there are very few studies conducted analysing the effects of both 
protein and physical activity on IGF-1, the majority of these studies have utilised 
military personnel or investigated protein as a post-exercise supplement for athletes.  
The use of IGF-1 in the military population is of particular relevance as a metabolic 
marker since troops are in a state of continual physical training, extreme stress and, 
likely, caloric deficit.  (111).  
In one study the effect of protein intake, physical activity and the IGF-1 response was 
evaluated while in a state of caloric deficit (112).  This study observed the influence of 
two levels of dietary protein intake and the effects of IGF-1 during eight days of caloric 
deficit and military exercise training.  Thirty-four men ages 24 +/- 0.3 years 
participated.  The militants performed an average of 16.5 MJ/day of exercise and had 
an intake of 6.5 MJ/day.  These men were divided into two groups: one receiving a 0.9 
g/kg dietary protein intake and the other received 0.5 g/kg of dietary protein.  IGF-1 
was measured before the intervention and on days four and eight.  The low-calorie but 
high-protein diet (0.9 g/kg body weight) blunted the decrease in total IGF-1 typically 
observed in a low-energy state (112).  However, even though the IGF-1 response was 
attenuated there was no difference in fat-free mass loss between the high and low 
protein groups.  Thus, the higher protein intake was successful in curtailing the IGF-1 
decrease associated with caloric restriction but it failed to have a systemic effect on 
fat-free mass preservation.  It should be noted that the lack of systemic response may 
be due to a caloric restriction too severe for IGF-1 preservation (112).  Another aspect 
to consider would be the military infantry candidates were only allowed four hours of 
sleep each night.  Thus, inducing more stress/catabolic actions into the participants 
life; it is possible that this continual state of stress did not allow IGF-1 to adequately 
perform its typical functions of repair and growth.  If typical sleep hours were 
observed the lack of systemic effect of fat-free mass preservation in the higher protein 
group might not have occurred.  
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The second population that has participated in research involving protein intake, 
exercise and the IGF-1 response is athletes.  Observation cross sectional evidence 
suggests that inactive individuals (n=21) who habitually follow a low-protein, low 
calorie diet have lower IGF-1 concentration and a reduced IGF-1 to IGFBP-3 ratio 
when compared to either age and sex matched controls (n=21) following a more 
typical western diet, or BMI matched endurance runners (n=21) (113).  The 
mechanism explaining this result is unknown.  However, it is theorised that a decrease 
in IGF-1 production resulting from lower protein intake accompanied by an increase 
in clearance rates may be a contributing factor (113).  Previous studies have 
supported this theory by showing a correlation between low dietary protein intake 
and reduced steady-state concentration of hepatic IGF-1 mRNA as well as an increased 
clearance of serum IGF-1 (113-115).  This study examined one group that had low-
protein and low-calorie, another that exercised, and a third Western diet group, which 
allowed for analysis of each group independently.  Future studies splitting the 
exercise group into a low-protein and low-calorie group as well as a Western diet 
control group would allow for an analysis of the effects of the combination of diet and 
exercise, like the previous study by Alemany et al.  
Studies investigating the relationship between protein and IGF-1 in relation to 
resistance training show mixed results.  Chandler et al (116) conducted a study 
analysing the effect of carbohydrate and/or protein supplementation after exercise on 
nine experienced weight lifters aged 21 to 35 years.  The four groups consumed either 
water, carbohydrate (1.5 g/kg body weight), protein (1.38 g/kg body weight), or 
protein and carbohydrate (1.06 g CHO/kg body weight, 0.41 g protein/kg body 
weight) immediately and two hours after resistance training.  There was no significant 
difference between supplements on the IGF-1 response (116).   However, the exercise 
protocol was not reported and, thus, it is not known if exercise was standardised 
between groups or if athletes simply continued with their usual training. Without this 
detail, it is difficult to know whether the nutrient composition of post exercise training 
supplements impacts IGF-1 response or if differences between groups in terms of 
training volumes and intensities have confounded the results.  
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In contrast, Willoughby et al conducted a well-controlled study with nineteen 
untrained male participants in which exercises and intensity were standardised.  They 
gave participants either 20 grams of protein or 20 g of dextrose placebo before and 
after resistance training (117).  Over the course of the ten week study the protein 
group produced significantly greater increases in fat-free mass, muscle strength, 
serum IGF-1 and IGF-1 mRNA.  The increases in fat-free mass, muscle strength and 
IGF-1 are indicative of utilisation of the mTOR pathway that promotes growth.  Thus, 
it would suggest that protein supplementation would be beneficial for increases in 
muscle mass and growth via an increase in IGF-1 (117).   
Unfortunately, most studies utilising an athletic population have only investigated the 
acute response to protein supplementation in response to exercise.  Longitudinal 
research would provide greater insight into the effect of chronic protein 
supplementation on muscle growth on the IGF-1 response.    
Section 2.5 Measurement of IGF-1 
A measurement of serum IGF-1 is typically obtained via a blood draw utilising a serum 
separating tube (containing silica particles and a serum separating gel).  However, a 
recent, and promising, article was published investigating the use of a salivary sample 
to measure IGF-1 in the future (118).  When conducting a blood draw for IGF-1 
measurement there are two main methods: radioimmunoassay (RIA) or ELISA.  The 
radioimmunoassay is most commonly used to measure total IGF-1 after ethanol 
extraction and the use of des-(1-3) IGF-1 as a ligand (119, 120).  The advantages of 
RIA are that it is highly sensitive and specific.  The disadvantages are that RIA uses 
radiolabelled reagents, which requires specially trained technicians that are licensed 
to handle radioactive material.  In addition, special storage is needed for radioactive 
material.  The high cost of radioactive disposal is also a drawback of this method 
(121).  
IGF-1 can also be measured via an ELISA (122).  There are currently over 594 
different ELISA kits available from over 42 different suppliers.  ELISA kits can vary by 
coatings, procedure, and cost.  In addition, each ELISA kit can have a different 
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sensitivity, range, and recovery percentage.  The advantages of ELISA is that they use 
reagents that are inexpensive and have a long shelf life.  ELISA is also highly specific 
and sensitive while simultaneously having a procedure that is quick and easily 
performed.  In addition, no radiation hazards occur during labelling or disposal of 
waste.  The disadvantages of ELISA measurement is that enzyme activity may be 
affected by plasma constituents.  Kits are commercially available but not cheap.  In 
addition, each kit is very specific to particular antigen.  False positives/negates are 
also possible using this method, especially with mutated/altered antigens (121). 
The research reviewed in the previous sections used a variety of sampling measures, 
which may have contributed to differences in results between studies. Most of the 
studies analysing the chronic effect of a variable on IGF-1 measured samples in a 
fasted, resting state.  Other studies looked at the influence of IGF-1 soon after exercise 
or protein intake, which has been shown above to alter IGF-1 concentration.  In 
addition, studies presented in the exercise IGF-1 section above observed a varied 
response after exercise when IGF-1 was measured mid-exercise and from five to 120 
minutes after exercise was concluded.  Thus, the time at which the IGF-1 sample was 
obtained varies greatly between studies and influences how the IGF-1 response is 
interpreted.  This may explain some of the inconsistency in the results.    
Moreover, there is a circadian rhythm associated with the modulation of growth 
hormone and IGF-1.  As previously described, the time period of early sleep is 
associated with growth hormone and IGF-1.  In later sleep, growth hormone levels fall 
and upregulation of IGFBPs is mediated by somatostatin causing a signal shift to 
favour the FOXO pathway.  IGF-1 levels do not fluctuate during the waking hours 
unless altered by activity or diet.  Thus, IGF-1 is expected to be at its natural peak 
during early sleep, and lowest during late sleep.  Therefore, differences in time of IGF-
1 measurement throughout the day could have added to the variability in results.  
Section 2.6 Applications 
Concentrations of IGF-1 and IGFBP-3 are associated with an increased risk of cancer.  
The amount of risk and correlation strength vary by cancer site as well as lifestyle 
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factors (47).  High circulating concentration of IGF-1 have been associated with an 
increased risk of prostate, breast, colorectal, and lung cancer (47, 123-126).  A meta-
analysis of IGF-1 and cancer calculated that high IGF-1 concentration increased a 
man’s risk of developing prostate cancer by 47 percent when compared to men with 
low IGF-1 concentration (47).    
Diet has a significant effect on circulating IGF-1 concentration.  High circulating IGF-1 
concentration promotes tumour development by increasing cell proliferation and 
decreasing apoptosis (113, 127-129).  A diet low in protein and calories reduces 
plasma IGF-1 concentrations (5, 104, 113).  On the contrary, individuals with a high 
protein intake, and thus high IGF-1 concentration, have four times the risk of cancer 
death (15).  Using dietary data available from 6,381 participants from the NHANES III 
over the age of 50 years (mean age of 65 years), who were followed up for 18 years of 
mortality outcomes it was found that for every 1.3 nmol/L increase in IGF-1 the risk of 
dying from cancer increased an additional nine percent for the high protein group (> 
20% of calories from protein) when compared to the low protein group (< 10% 
calories from protein).  Overall, participants who reported a high protein intake had a 
75% increase in overall mortality and a four times greater risk of cancer death in the 
18 year follow up.  The large sample size and multiple year follow up utilized make 
this study impressive.  In addition, the ability to link a specific increase in IGF-1 to a 
percentage increase in mortality risk is valuable for clinical applications in order to 
analyse risk factors and determine when a dietary intervention might be indicated to 
lower a person’s IGF-1 concentration.   
In contrast to IGF-1, there is a negative association between IGFBP-3 and cancer.  A 
systematic review and meta-regression analysis of case-controlled studies identified 
an association between high IGFBP-3 concentration and a decreased cancer risk (47, 
130, 131).  The possible protective nature of IGFBP-3 has been displayed in a smoking 
population.  Cigarette smoking reduces IGFBP-3 concentration in a dose-related 
response and individuals who smoke have a high risk of lung cancer (47).  Thus, it is 
possible that one mechanism behind the high rates of lung cancer in smokers could be 
due to their low IGFBP-3 concentration.     
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Resistance training, and exercise in general has been shown to reduce the risk of colon 
cancer (132).  A 40 to 50 percent decrease in cancer risk has been shown for highly 
physically active people (133, 134).  There appears to be a dose-response relationship 
whereby people with the highest levels of physical activity display the lowest cancer 
risk (133, 134).   
However, exercise is not limited to a protective mechanism against cancer.  It has also 
been shown to help reduce the number of cancer deaths for those who are already 
diagnosed with cancer (133).  Haydon et al. used the Melbourne Collaborative Cohort 
Study data and identified 526 cases of colorectal cancer (443 of those diagnosed 
individuals had IGF-1 and IGFBP-3 measures).  The cancer patients were followed for 
an average of 5.6 years after diagnosis and grouped based on their activity level into 
either a highly physically active or not highly physically active group.  Colorectal 
cancer patients that were physically active showed an increase of IGFBP-3 by 26.2 
nmol/l and a 48 percent reduction in colorectal cancer deaths (133).  While the 
benefits of physical activity were displayed across all stages of cancer diagnoses, the 
value was greatest for those with stage II and II cancer (133).   
A study by Eberhardt et al. looked exclusively at stage III colon cancer patients 
receiving chemotherapy and found that patients in the highest quintile of physical 
activity were 35 percent more likely to survive disease free when compared to 
patients in the lowest physical activity quintile (135).  One possible reason for the 
association between IGFBP-3 and decreased cancer risk lies the ability for IGFBP-3 to 
induce apoptosis and inhibit growth via the transforming growth factor B pathway 
(133, 136).  Thus, an increase in circulating IGFBP-3 would produce an increase in 
apoptosis, inhibit cell growth, and influence cancer outcomes/risk.  
Section 2.7 Conclusion 
Studies have repeatedly shown that plasma  IGF-1 concentration is regulated 
predominantly by nutrient intake (8).  Both total caloric intake as well as protein 
intake can modulate IGF-1 concentration.  Large reductions in caloric intake can 
produce a significant decrease in IGF-1 (8, 9).  Dietary protein intake has a dose 
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response relationship with IGF-1 concentration; therefore, even a small reduction in 
dietary protein can cause a proportional decrease in IGF-1 concentration (104).  
However, the time course of the IGF-1 response to a single dose of dietary protein is 
currently unknown.  It is also unknown how IGF-1 concentration responds to a diet 
chronically high in dietary protein.  
The literature regarding the IGF-1 response to exercise is inconsistent. Differences in 
study design in terms of exercise type and intensity, training history, and duration of 
intervention have contributed to the lack of clarity in this area.  Further research is 
needed in order to determine both the acute, and chronic effects of exercise on IGF-1 
concentration.   
A high concentration of IGF-1 and low concentration of IGFBP-3 are associated with 
an increased risk of cancer. Diets low in protein intake reduce plasma IGF-1 
concentration and reduce the risk of cancer (5, 104, 113).  On the contrary, individuals 
with a high protein intake, and thus high IGF-1 concentration, have four times the risk 
of cancer death (15).  Resistance training, and exercise in general has been shown to 
reduce the risk of colon cancer (132) but whether the effect of exercise on IFG-1 is  a 
contributor to this association remains unclear.   
The method of IGF-1 measurement (RIA or ELISA) and timing of sample acquisition 
(resting and fasted or following an exercise/dietary intervention) influence the IGF-1 
measurement outcomes.  RIA allows for a high sensitivity and specificity 
measurement but radiation makes working with it difficult.  ELISA provides a cheaper 
and easier way of measuring IGF-1 but sensitivity and specificity vary between the 
type of kit utilized.  In addition, there is a circadian rhythm to IGF-1 release that needs 
to be taken into account when comparing measures taken at different time points.  
In totality, this PhD aimed to quantify the previous literature on dietary protein or 
exercise on IGF-1, complete an intervention study to see the effects and time-course of 
these stimuli (both independently and combined) within the same individuals, then 
investigate whether the previously identified associations hold true in a large cross-
sectional study.  
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3. STATEMENT OF AIMS 
 
1) To systematically review the literature to investigate the relationships between 
dietary protein, and exercise on IGF-1. 
2) To investigate the effects of acute ingestion of dietary protein on free IGF-1 
concentration with and without prior acute exercise.   
3) To investigate the association between habitual diet and physical activity on 
IGF-1 concentration in a large epidemiological cohort. 
Section 3.1 Statement of Hypotheses 
1) Increased habitual intake in dietary protein will increase resting fasted IGF-1 
concentration. 
2) Increased habitual physical activity levels will decrease resting fasted IGF-1 
concentration. 
3) Habitual high protein intakes combined with high levels of physical activity will 
result in lower rested fasting IGF-1 concentration than with high protein 
intakes alone.    
4) A single acute bout of intensive exercise will increase free IGF-1 concentration.  
5) A single dose of protein will acutely increase free IGF-1 concentration. 
 A single acute bout of intensive exercise, followed by a dose of dietary protein, 












4. DIETARY PROTEIN AND IGF-1: SYSTEMATIC REVIEW AND META-ANALYSIS 
 
Section 4.1 Introduction 
IGF-1 concentration is altered in states of undernutrition (2-4) and overnutrition (2, 
137-141).  These associations are thought to be driven by the associated changes in 
protein intake, and interestingly higher protein intakes have been associated with 
increased cancer risk (142, 143).  Thus, if high dietary protein is associated with IGF-
1, and if high IGF-1 concentration is also associated with cancer, then IGF-1 may be a 
mediating factor in the link between dietary protein and cancer (144). However, to 
date the results of studies assessing the relationship between dietary protein and IGF-
1 concentration have been inconsistent.  Therefore, the purpose of this study is to 
systematically review and analyse the association between dietary protein and IGF-1 
concentration. 
 
Section 4.2 Methods 
This review was performed in accordance with the approach outlined in the Cochrane 
Handbook for Systematic Reviews of Interventions and follows the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) (145).   
4.2.1 Search Strategy and Study Selection 
An electronic search was performed for publications prior to 5 October 2017 using 
Scopus, PubMed, Sport Discus, Web of Science, and Academic Search Complete, and 
updated on 25 February 2019.  The search was designed to identify peer reviewed 
scientific articles containing results of research relevant to IGF-1 and protein.  The 
terms used for the search were: (“IGF-1” OR "Insulin Like Growth Factor 1" OR “IGF-
I”) AND (“protein”), the search results were filtered to include papers published in 
English that studied adult human participants (18-65 years) in a non-diseased state.  
Participants taking metabolism and/or hormone altering medications were excluded 
as well as studies that intentionally subjected participants to a negative energy 
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balance for the purpose of weight loss.  No publication date restrictions were imposed.  
Manual searches of the reference lists of studies that met all eligibility criteria were 
performed.  Using Covidence systematic review software (Covidence, Melbourne, VIC, 
Australia), two reviewers independently screened titles and abstracts, assessed full 
text papers for eligibility, and extracted data from all papers included in the review.  
Conflicts about selection of studies or data extraction were resolved by consensus.  
The flow of information through the review is shown in Fig 1. 
 
Figure 1: Dietary Protein and IGF-1: Publications included in the systematic review and meta-analysis 
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4.2.2 Eligibility Criteria and Screening 
Eligible studies were intervention or cross-sectional studies. 
4.2.3 Population 
Study populations consisted of non-diseased, non-pregnant, adults from 18 to 65 
years of age.   
4.2.4 Intervention or Exposure 
Eligible intervention studies included any study designed to test the effect of an 
increase in dietary protein on measures of IGF-1.  The intervention could include a 
single supplemental dose of protein or an increase in overall daily protein intake as 
long as the participants were not also in acute or chronic negative energy balance.  For 
the cross-sectional studies the exposure was dietary protein intake.   
4.2.5 Comparison 
For intervention studies, the comparison was the IGF-1 concentration before and after 
the intervention period.  For cross-sectional studies, the comparison was higher 
protein intake.  
The outcome of interest for the intervention studies was mean total Insulin Like 
Growth Factor-1 concentration. The outcome of interest for the cross-sectional studies 
was the association between dietary protein and IGF-1concentration represented as a 
beta regression coefficient.  Studies that reported the association between dietary 
protein and IGF-1 in a form other than mean IGF-1 concentration (intervention 
studies) or beta regression coefficients (cross-sectional studies) were contacted to 
supply the raw data.  If the authors did not supply the requested data their study was 
excluded from the meta-analysis (n=8).   
4.2.6 Data Extraction and Quality Assessment 
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Extracted information included: IGF-1 concentration (alone, or before and after for 
intervention studies), IGF-1 units of measure, author, year of publication, design, 
study duration, type of protein, number of participants, anthropometric participant 
data, diet composition (when reported), dietary protein quantity before intervention, 
dietary protein quantity after intervention.  Outcome variables of the extracted 
studies that were included in the meta-analysis were: IGF-1 concentration (for 
intervention studies) or regression coefficients from the association between dietary 
protein and IGF-1 concentration (for cross-sectional studies).  For cross-sectional 
studies, in accordance with the Cochrane Handbook, estimates from the most adjusted 
model were extracted and were then standardised to estimate the association 
between dietary protein (g/day) and IGF-1 concentration (nmol/L).  Thus, each beta-
coefficient represents the change in IGF-1 concentration in nmol/L per 1 g increase in 
dietary protein intake.  These units were chosen because it was the most common unit 
reported across the studies.   
Two reviewers independently assessed study quality.  The intervention studies were 
assessed using the Jadad scale (146), which rates study quality based on: 
randomisation, double-blinding, withdrawals and drop-outs (minimum total score 0, 
maximum total score 5).  An intervention study with a score higher than 2 was 
considered a study of good quality (147).  It should be noted that one of the factors 
involved in rating with the Jadad scale includes a point for double-blinding.  Seven of 
the intervention study groups involved alterations in diet such as addition of 
meat(148), dairy(149), or other high-protein food in which double blinding is not 
plausible; however, they still lost a point for study quality.  The cross-sectional studies 
were assessed using the Newcastle-Ottawa quality assessment tool (150), which rates 
study quality based on: representativeness of the sample, sample size, non-
respondents, ascertainment of the exposure, comparability, assessment of outcome, 
and statistical test (minimum total score 0, maximum total score 10).   
4.2.7 Statistical Analysis 
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Meta analyses were conducted using ADMETAN commands in STATA (version 15.1 
for Windows) to calculate the summary estimates for the intervention and cross-
sectional studies.  An IVhet model was used for the pooled analysis.   
For intervention studies, the outcomes were expressed as a standardised mean 
difference comparing IGF-1 concentration before and after dietary intervention.  Since 
reporting of IGF-1 units were not uniform across all studies, a standardised mean 
difference was used instead of a weighted mean difference. Where multiple arms of 
the same intervention study involved different doses of protein, the sample size of the 
pre-intervention group was split between the different arms in accordance with the 
Cochrane Handbook for Systematic Reviews of Interventions (145).  A meta regression 
was used to assess the modifying effect of the dose of dietary protein on IGF-1, one 
subgroup analysis was performed to assess the modifying effect of duration of 
increased protein intake (<10 days or >10 days) on changes in IGF-1 concentration, 
and a separate subgroup analysis was performed to investigate the effect of protein 
type (soy vs non soy) on changes in IGF-1 concentration.   
For cross-sectional studies in which results were reported separately for women and 
men (151), or postmenopausal and premenopausal (152), we performed an IVhet 
model meta-analysis in STATA to calculate a summary estimate for the combined 
subgroups (i.e. men and women combined, premenopausal and postmenopausal 
combined).   
For both the intervention and cross-sectional study analyses, I-squared values were 
used to judge the degree of heterogeneity, with values above 50% considered 
important.  Sensitivity analyses and funnel plots for publication bias were conducted 
for both intervention and cross-sectional studies (data not shown).   
Section 4.3 Results 
A total of 7,006 publications were identified through the database searches.  Overall, 
18 intervention study groups included a total of 351 participants (148, 149, 153-159) 
met the inclusion criteria for review (Figure 1). Of these 18 study groups, 13 showed a 
positive effect of dietary protein on IGF-1 concentration, three showed a negative 
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effect, and two study groups did not report the results of the intervention.  The study 
characteristics and results are detailed in Table 2.  
 
 
Table 2: Dietary Protein and IGF-1 Intervention Study Characteristics and Results 
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Serum, IRMA 7 16.9 6.2 21.2 6.2 
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*Study did not report overall protein intake for the day, only the single acute bolus of protein 
ᵻStudy did not report weight of participants so value in table is g of protein administered per day.  
*** Study did not report weight of participants so value in table is g of protein administered per day.  
‡Study reported IGF-1 in Units/mL 









Three of the intervention study groups included in the systematic review were 
excluded from the meta-analysis during the process of data extraction and analysis.  
Kinsey et al. (164) investigated the effects of a single dose of protein over 24 h 
(morning before and morning after a 30 g pre-sleep dose of whey/casein mix).  This 
was the only study that measured the response to a single dose of protein, and 
therefore, a decision was made not to include it in the meta-analysis.  Kahlil et al. 
(163) did not report the values of the post-intervention IGF-1 concentration; 
therefore, this study was unable to be included in the meta-analysis (163).  Arjmandi 
et al. (159) revealed that, while unintentional, participants were in a negative energy 
balance at the conclusion of the study.  Since we cannot be sure that IGF-1 
concentration was not confounded by this negative energy balance the study was 
removed from the meta-analysis.      
When compared to baseline protein intake, interventions that increased dietary 
protein resulted in increases of IGF-1 concentration (Cohen’s d= 0.62, 95% CI -0.10 to 
1.33).  However, there was high heterogeneity between study groups (I2 = 87.3%, p = 
0.000).  Subgroup analysis revealed no significant difference in the effect of dietary 
protein on IGF-1 concentration when study groups were separated by study duration 
(Figure 2) (p = 0.147).  Study groups in which the increase in dietary protein occurred 
for 10 days or less resulted in an increase in IGF-1 concentration (Cohen’s d= 0.45, 
95% CI 0.03 to 0.86) and exhibited low heterogeneity (I2 = 37.8%).  Study groups with 
a duration greater than 10 days had a larger change in IGF-1 concentration (Cohen’s 
d= 0.74, 95% CI -0.77 to 2.25), but exhibited high heterogeneity (I2= 95.1%).  A 
separate subgroup analysis revealed no significant difference in the effect of protein 
type (soy vs non soy) on IGF-1 concentration (p=0.894) (data not shown).  A meta 
regression of all study groups (regardless of duration) indicated no evidence of a 
linear association between the change in protein intake from baseline, and the 
magnitude of change in IGF-1 concentration (Cohen’s d= -0.239, 95% CI -1.68 to 1.20).  
In addition, a sensitivity analysis was conducted, resulting in the exclusion of Kang et 
al. (2017) which changed the magnitude of the effect estimate, but did not account for 
42 
the heterogeneity.  A funnel plot revealed some evidence of publication bias (data not 
shown).        
 
 
Figure 2: Dietary Protein and IGF-1: Inverse variance heterogeneity (Ivhet) model of standard mean 
difference (SMD) (95% confidence interval [CI]) of dietary protein’s effect on Insulin Like Growth 
Factor-1 concentration in intervention study groups with subplots for length of intervention. 
Fifteen cross-sectional study groups met the inclusion criteria for review, all of which 
were of cross-sectional design. Nine of these study groups showed a positive effect of 
dietary protein on IGF-1 concentration  (151, 152, 165-170), five showed a negative 
effect (171-175), and one study showed a positive effect for animal but not plant 
protein (176) (Table 3). Eight cross-sectional study groups did not report data 
conducive to a meta-analysis (i.e. they did not report a beta co-efficient n=6 or 
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reported quartiles of intake n=2) (Table 3).  These authors were contacted but none 
replied with the requested data, therefore, they were unable to be included in the 
meta-analysis.  As a result, seven cross-sectional study groups were included in the 
meta-analysis.     
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The included cross-sectional study groups involved of a total of 6,879 participants 
(151, 152, 165-167, 171-173).  The study groups characteristics and outcomes of 
these study groups are displayed in Table 2. The cross-sectional study groups 
demonstrated that, on average IGF-1 concentration was 0.03 nmol/L higher for every 
1 g/day increment in dietary protein (95% CI -0.01 to 0.07 nmol/L) (Figure 3).  
However, the I2 statistic indicated a high level of heterogeneity between study groups.  
Attempts to investigate the causes of this heterogeneity, including a subgroup analysis 
based on study quality and whether or not IGF-1 concentration was log transformed 
prior to analysis, failed to reveal the source of heterogeneity (data not shown).  In 
addition, a sensitivity analysis was conducted and did not result in any changes nor 
account for the heterogeneity.  A funnel plot revealed some evidence of publication 
bias.        
 
Figure 3: Protein and IGF-1: Inverse variance heterogeneity (Ivhet) model of regression coefficient (ꞵ) 
(95% confidence interval [CI]) of dietary protein’s effect on Insulin Like Growth Factor-1 concentration 
in cross-sectional study groups. 
Section 4.4 Discussion 
Our meta-analyses of intervention and cross-sectional data indicate a positive 
relationship between dietary protein and IGF-1.  However, the high heterogeneity 
associated with the summary estimates produced here does somewhat limit the 
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confidence we have in the magnitude of the associations of these estimates. Insulin 
like growth factor-1 is involved in many physiological processes, making it difficult to 
isolate specific factors that contribute to a change in IGF-1 concentration.  IGF-1 
concentration varies by age (151), sex (178), body mass index (151, 179, 180) , height 
(151), weight (151), and time of day (181, 182).  In addition, dietary intake is a 
challenging variable to control, especially when participants are not contained to a 
laboratory setting. Given the known impact of a negative energy balance on IGF-1 
concentration (59), we excluded any studies in which the participants were 
intentionally in a negative energy balance.  Thus, we cannot discount the possibility 
that participants chose to substitute a high protein meal with a high carbohydrate 
meal.  This substitution had the potential to influence study results since both insulin 
and IGF-1 share the PI3K signalling pathway (183).  However, since it is impossible to 
vary protein content and match both energy and other macronutrients, the meta-
analysis was designed to control for energy balance rather than carbohydrate.  Thus, 
the high level of heterogeneity may be attributed to the small number of study groups 
or lack of control for other external factors that influence IGF-1 concentration (age, 
sex, circadian rhythm, physical activity, carbohydrate intake, etc.) (181, 182, 184-
187).    
The only summary estimate produced by the current analysis that was associated 
with an acceptable level of heterogeneity was that for intervention study groups in 
which the protein supplementation lasted less than 10 days.  The magnitude of the 
elevation in IGF-1 concentration in response to protein supplementation is consistent 
with what would be considered a medium effect (188).  Given that IGF-1 
concentration has been associated with increased cancer risk, this increase may be 
clinically relevant. There was a very high level of heterogeneity associated with the 
longer duration intervention study groups, (I-squared = 95.1%).   Thus, it is difficult to 
draw definitive conclusions about the large effect size estimated by this analysis.     
Interestingly, meta-regression provided no evidence of a dose response relationship 
between the increase in protein provided by the intervention, and the magnitude of 
difference in IGF-1 concentration at the completion of the control and intervention 
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arms of each study.  However, the small number of study groups, (n=16) limits our 
ability to confidently exclude the possibility that a dose response relationship may 
indeed exist.    
Aggregate data from seven cross sectional study groups indicate that on average IGF-1 
concentration was 0.03 nmol/L higher for every 1 g/day increment in dietary protein 
(95% CI -0.01 to 0.07 nmol/L).  A 1 g/day increase in dietary protein represents a 
1.81% increase in protein RDI for and 0.15% increase in daily median energy intake 
for males in New Zealand (189).  A 1 g/day increase in dietary protein represents a 
2.22% increase in protein RDI and 0.22% increase in daily median energy intake for 
females in New Zealand (189).  However, again the high heterogeneity associate with 
this estimate does limit our confidence in magnitude of this estimate.   
The type of protein needs to be considered when interpreting the results.  The cross-
sectional studies were limited to total protein only (combination of all sources of 
protein consumed throughout the day) and any effect of type of protein (e.g. soy only 
or meat only protein sources) was not evaluated.  There were not enough intervention 
studies to conduct separate analyses for each type of protein: meat protein (1 study), 
milk-based protein (1 study), Maillard reactive whey protein (1 study), soy protein (5 
study groups), and non-specified total protein intake (6 study groups).  However, in 
search of sources of heterogeneity a separate analysis with subgroups for soy and 
non-soy study groups was conducted.  The results indicated that the subgroup 
differences were not only insignificant (p=0.894) but the heterogeneity of the soy 
group was so high (I2=94.4%) that we cannot be sure that these study groups 
accurately represent the effects of soy protein on IGF-1 concentration.  Previous 
epidemiological studies have highlighted that the relationship between protein and 
longevity may be stronger with animal protein, compared to non-animal protein 
(190).  If animal protein is more critical to longevity then it would be reasonable to 
expect animal-based proteins to impact IGF-1 concentration, and thus mutagenicity, to 
a larger extent than plant proteins.  In addition, previous studies have demonstrated 
that soy protein containing phytosterols may play a role in carcinogenesis through the 
inhibition of carcinogen production and promotion of apoptosis of cancerous cells 
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(191).  More research is needed investigating total protein consumption as well as 
each individual type of protein to see if this reasoning has merit.     
The most consistent, and marked result from this analysis however, is that the 
direction of the association is consistent across both intervention and cross-sectional 
studies, indicating that dietary protein intake is indeed associated with IGF-1 
concentration.  A recent meta-analysis by Kaxemi et al. (192) confirmed this positive 
direction of effect when they reported a significant increase in circulating IGF-1 levels 
in response to increases in dietary protein (SMD= 0.05 nmol/L).  Providing a more 
confident estimation of the magnitude of association between dietary protein and IGF-
1 concentration will help advise those concerned about risk of cancer on how to best 
modulate protein intake to mitigate the risk of cancer incidence.  
There are two plausible mechanisms that drive the association between dietary 
protein and IGF-1.  The first of which is shown in Figure 4 with the effects of increased 
dietary protein on post receptor signalling of IGF-1.   
The second mechanistic possibility involves post-receptor resistance (6).  Previous 
studies have shown that a decrease in protein intake leads to post-receptor resistance 
to the action of growth hormone (100).  Thus, reduced growth hormone binding does 
not mediate IGF-1 concentration (101).  Reduced protein intake decreases hepatic 
IGF-1 mRNA in proportion to the decline in serum IGF-1 (101).  Therefore, it can be 
deduced that alterations in serum IGF-1 are partially determined by transcriptional 
events (6).   
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Figure 4: IGF-1 molecular signalling pathway diagram. Adapted from (193). 
 
4.4.1 Strengths and Limitations 
The major limitation of any meta-analysis is that it relies on the quality of the studies 
that underpin it. The high level of heterogeneity associated with the intervention 
studies lasting longer than 10 days, and in the cross-sectional studies, reflects the high 
variability in study design, and also highlights the lack of well designed, appropriately 
powered studies conducted in this area.  Additionally, it is likely that publication bias, 
which is not uncommon when both study number and sample size are small, has 
inflated (to some degree) the summary estimates presented here.  All methods of 
dietary assessment are prone to both systematic and random bias (194), therefore, 
the accuracy of the measurement of protein in cross-sectional studies, or changes in 
protein intervention studies is limited by these biases.  .  Finally, our literature search 
was limited to the English language, and as such, we cannot exclude the possibility 
that we have overlooked research published in another language. The main strength 
of the present study is that it provides a systematic review and quantitative estimate 
of the association between dietary protein and IGF-1 concentration.    
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Section 4.5 Conclusions 
We believe the results of these meta-analyses provide enough evidence to suggest that 
there is a positive association between protein and IGF-1 concentration that is likely 
of a clinical meaningful magnitude.  In order to provide a confident and precise 
estimate of the magnitude of the association between dietary protein and IGF-1 we 
will need more well-designed, and appropriately powered randomised controlled 
trials.  Ideally these studies would last longer than 10 days and take measurements of 
















5. EXERCISE AND IGF-1: SYSTEMATIC REVIEW AND META-ANALYSIS 
Section 5.1 Introduction 
Since IGF-1 concentration is known to modulate increases in muscle mass (59, 62) ,  
and muscle mass can be enhanced in response to exercise, one might expect IGF-1 
concentration to increase after exercise.  There is a large body of research involving 
exercise and IGF-1 concentration (105-107, 195); however, the results are 
inconsistent both in terms of direction and magnitude of effect.  Therefore, the 
purpose of this study was to conduct a systematic review and meta-analyses of the 
association between a single bout of exercise and total IGF-1 concentration in 
circulation. 
Section 5.2 Methods 
This review was performed in accordance with the approach outlined in the Cochrane 
Handbook for Systematic Reviews of Interventions and follows the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) (145).   
5.2.1 Search Strategy and Study Selection 
An electronic search was performed for publications prior to 5 October 2017 and 
updated through 13 December 2019 using Scopus, PubMed, Sport Discus, Web of 
Science, and Academic Search Complete.  The search was designed to identify articles 
containing results of research relevant to IGF-1 and exercise.  The terms used for the 
search were: (“IGF-1” OR "Insulin Like Growth Factor 1" OR “IGF-I”) AND (“exercise” 
OR "physical activity" OR sport* OR exercise* OR “exertion” OR “training”).  The 
search results were subsequently screened to determine if they were peer reviewed 
articles measuring serum or plasma IGF-1 concentration, published in English, studied 
adult human participants (18-65 y) in a non-diseased state, not taking metabolism 
and/or hormone altering medications, and not in negative energy balance.  
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Using Covidence systematic review software (Covidence, Melbourne, VIC, Australia), 
two reviewers independently screened titles and abstracts, assessed full text papers 
for eligibility, and extracted data from all papers included in the review.  Conflicts 
about selection of studies or data extraction were resolved by consensus.  The flow of 
information through the review is shown in Fig 4. 
 
Figure 5: Exercise and IGF-1: Publications included in the systematic review and meta-analyses 
5.2.2 Eligibility Criteria and Screening 
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Eligible studies were intervention studies in which total IGF-1 was measured before 
and after exercise. 
5.2.3 Population 
Study populations consisted of non-diseased, non-pregnant, adults from 18 to 65 
years of age.   
5.2.4 Intervention or Exposure 
Eligible studies included any study designed to test the acute effect of exercise on 
measures of total IGF-1.  The intervention could include any mode or duration of 
exercise. 
5.2.5 Comparison 
For studies without a control group, the comparison was IGF-1 concentration before 
and after the completion of exercise.  For studies with a control group, the comparison 
was IGF-1 concentration after exercise in the treatment group versus the control 
group (no exercise), at the same time.    
5.2.6 Outcome 
The outcome of interest was mean total IGF-1 concentration.  Once studies had been 
identified it became apparent that there were large differences in study design that 
made comparisons between studies difficult.  Therefore, it was decided to limit 
studies included in the systematic review and meta-analysis to those that measured 
total IGF-1 (bound and unbound).  Free IGF-1 is not equivalent to total IGF-1 due to 
the influence of binding proteins, thus free and total IGF-1 concentrations are unable 
to be compared (196).  It was also decided to limit the review to only include studies 
that measured IGF-1 concentration immediately before, and within one h of the 
exercise bout.  This time-frame was chosen because it captured the greatest number 
of studies, represents the acute effect of exercise, and reduces the variability due to 
sampling times, resulting in a more homogeneous group of studies.  Studies that 
reported the association between physical activity and IGF-1 in a form other than 
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mean IGF-1 concentration were contacted to supply the raw data.  If the authors did 
not supply the requested data their study (n= 117) was excluded from the meta-
analysis; however, the study characteristics and results were summarised and 
presented in Table 6 (See Appendix D).   
5.2.7 Data Extraction and Quality Assessment 
Extracted information included total IGF-1 concentration (before and after when 
there was no control group or post exercise for the control and treatment group), IGF-
1 units of measure, author, year of publication, design, exercise duration, type of 
exercise, number of participants, and anthropometric participant data.  IGF-1 
concentration was the outcome variable of the extracted studies included in the meta-
analysis.   
Two reviewers independently assessed study quality.  The studies were assessed 
using the Jadad scale (146), which rates study quality based on: randomisation, 
double-blinding, withdrawals and drop-outs (minimum total score 0, maximum total 
score 5).  A study with a score higher than 2 was considered a study of good quality 
(147).  It should be noted that one of the factors involved in rating with the Jadad scale 
includes a point for double-blinding.  All studies involve exercise, for which double 
blinding is not possible; however, they still lost a point for study quality.   
5.2.8 Statistical Analysis 
Meta analyses were conducted using ADMETAN commands in STATA (version 15.1 
for Windows) to calculate the summary estimates.   
For studies without a control group, the outcomes were expressed as a standardised 
mean difference (Cohen’s d) in IGF-1 concentration before and after exercise.  For 
studies with a control group, the outcomes were expressed as a standardised mean 
difference (Cohen’s d) comparing IGF-1 concentration after exercise in the treatment 
group and at the same time point without exercise in the control group.  Where 
multiple arms of the same intervention study involved different types or doses of 
exercise, the sample size of the pre-intervention group was split between the different 
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arms in accordance with the Cochrane Handbook for Systematic Reviews of 
Interventions (145).  Subgroup analyses were performed to assess any modifying 
effects of type of exercise, mode of exercise, and duration of exercise on changes in 
IGF-1 concentration.  
I-squared values were used to judge the degree of heterogeneity, with values above 
50% considered important.  Sensitivity analyses and funnel plots for publication bias 
were conducted, which did not result in the exclusion of any studies (data not shown).   
Section 5.3 Results 
A total of 4,006 publications were identified through the database searches.  Overall 
211 studies (187 studies without a control group and 24 studies with a control group) 
including a total of 3,685 participants (3,254 participants without a control group and 
431 participants with a control group) (148, 149, 153-159) met the inclusion criteria 
for the systematic review (Figure  5, 6, and 7). Of these 211 studies, 150 showed a 
positive effect of exercise on IGF-1 concentration, 47 negative, 8 no change, and 6 did 
not report a direction of effect.  The study characteristics and results are detailed in 
Tables 4, 5, and 6 (See Appendix B, C, and D).  
 
Figure 6: Exercise and IGF-1: Summary estimate (expressed as Cohen’s d with 95% confidence 
interval) for the effect of exercise on total IGF-1 concentration for each type of exercise in studies 
without a control group. 
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Figure 7: Exercise and IGF-1: Summary estimate (expressed as Cohen’s d with 95% confidence 
interval) for the effect of exercise on total [IGF-1] for each type of exercise in studies with a control 
group. 
One hundred and seventeen studies met the inclusion criteria for the systematic 
review but did not present data in a way amenable to a meta-analysis: 102 studies 
presented data in a graphical but not numerical format, 6 studies reported the percent 
change in IGF-1 concentration, 3 studies reported results qualitatively, 4 studies 
reported results as a correlation between IGF-1 concentration and other hormones, 
and 2 studies compared change in IGF-1 concentration between rather than within 
conditions.  The majority of these studies exhibited a positive effect of exercise on IGF-
1 concentration (85 studies showed a positive direction of effect, 18 negative, 8 no 
change, and 6 did not report direction of effect) (Table 6).   
Results from 80 studies that compared pre and post exercise IGF-1 concentrations 
without a control group, with a total of 2,234 participants, showed that exercise 
resulted in an increase in total IGF-1 concentration (Cohen’s d= 0.24, 95% CI 0.14 to 
0.31).  However, there was evidence of high and significant heterogeneity (I2 = 73.4%, 
p < 0.001).  Subgroup analysis revealed a significant effect of exercise type on IGF-1 
concentration (Figure 6) (p <0.001).  Resistance exercise (37 studies with 494 
participants: Cohen’s d= 0.21, 95% CI 0.09 to 0.34, I2= 53.6%), sprint (25 studies with 
423 participants: Cohen’s d= 0.41, 95% CI 0.27 to 0.55, I2 = 73.7%) and combined 
sprint and resistance exercise (4 studies with 38 participants: Cohen’s d= 1.29, 95% CI 
0.77 to 1.81, I2 = 72.1%) all resulted in increases in IGF-1, however heterogeneity was 
high and significant across all subgroups.  Ultra-endurance racing (2 studies with 16 
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participants: Cohen’s d= -3.23, 95% CI -4.32 to -2.13, I2 = 0.0%) and endurance 
exercise (8 studies with 88 participants: Cohen’s d= -0.55, 95% CI -0.86 to -0.23, I2 = 
74%) both decreased IGF-1 concentration.   Heterogeneity was high for the endurance 
exercise, but low for ultra-endurance racing.  Exercise with blood flow restriction 
(BFR) did not significantly change IGF-1 concentration but had a low heterogeneity (4 
studies with 49 participants: Cohen’s d= -0.12, 95% CI -0.52 to 0.28, I2 = 10.3%).  
Attempts to further investigate the causes of heterogeneity, including subgroup 
analyses based on exercise mode (e,g cycling, running, skiing, team sports) and 
duration (less than 30 min, 30 min to 2 h, greater than 2 h) failed to explain the source 
of heterogeneity (data not shown).   
Results from 14 studies that compared post-exercise IGF-1 concentration with the 
same time point in a control group that did not perform exercise, with a total of 231 
participants, showed that exercise resulted in an increase in total IGF-1 concentration 
(Cohen’s d= 0.351, 95% CI 0.043 to 0.659).  However, there was evidence of high and 
significant heterogeneity (I2 = 83.9%, p <0.001).  Subgroup analysis revealed a 
significant effect of exercise type on IGF-1 concentration (Figure 7) (p < 0.001).  BFR 
exercise (1 study with 18 participants: Cohen’s d= 2.72, 95% CI 1.32 to 4.12, I2 = N/A) 
and resistance exercise (6 studies with 128 participants:  Cohen’s d= 0.65, 95% CI 
0.23 to 1.06, I2= 87.3%) resulted in increases in IGF-1 concentration.  The 
heterogeneity was high (I2>50%) for resistance exercise.  Endurance exercise (5 
studies with 64 participants: Cohen’s d= -0.37, 95% CI -0.94 to 0.20, I2= 80.4%) and 
sprint exercise (2 studies with 21 participants: Cohen’s d= -0.25, 95% CI -1.16 to 0.67, 
I2= 0.0%) did not significantly change IGF-1 concentration.  The heterogeneity was 
high for endurance but low for sprint exercise type.  The same subgroup analyses 
mentioned above with studies that compared pre and post exercise IGF-1 
concentrations without a control group failed to explain the source of heterogeneity 
(data not shown).   
Section 5.4 Discussion 
Our systematic review and meta-analyses indicate an overall positive relationship 
between exercise and total IGF-1 concentration.  However, the high heterogeneity 
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associated with the summary estimate produced by the meta-analysis does somewhat 
limit the confidence we have in the overall magnitude of this estimate.  Subgroup 
analysis revealed type of exercise was a source of heterogeneity with a different 
direction of effect for different types of exercise. 
 
The most novel, although unsurprising finding of our meta-analysis was the trend for 
resistance exercise to increase and endurance exercise to decrease total IGF-1 
concentration.  This was not particularly surprising because resistance exercise 
frequently results in increases in muscle mass, which relies on mTOR pathway 
upregulation, and IGF-1 contributes to its upregulation (197).    Given the timing of 
IGF-1 measurements for all of the included studies (within 1 h after exercise), the 
most likely mechanism of release being captured by this sampling window is the 
release of IGF-1 from the skeletal muscle via autocrine and paracrine signalling.  
Induction of hepatic IGF-1 release would be unlikely within this time period.  
Therefore, the appearance of IGF-1 in circulation acutely after exercise is most likely 
governed by  skeletal muscle release caused by contraction (23). 
   
While the plausible source of IGF-1 release and action with resistance exercise has 
been identified as IGF-1 receptors on the muscle membrane, in the presence of IGF-1, 
stimulating the PI3K/AKT/mTor pathway there are three other factors that may 
contribute to increases in muscle mass. The first contributor relies on IGF-1’s insulin-
like properties, specifically metabolic and anabolic properties (198).  This insulin-like 
effect increases amino acid uptake (199), increases glucose uptake and oxidation in 
muscle as well as adipose tissue (198).  The second factor involves endogenous 
muscle production of IGF-1 and autocrine signalling (198, 200).  The third, and most 
recently discovered, factor that contributes to increases in muscle mass emphasises 
the role of injury and repair in stimulating muscle growth (200).  When a myofibril is 
injured a myofibre dies, leaving basal lamina and satellite cells at the site of injury.  
The death of the myofibre triggers satellite cells to begin the regeneration process (59, 
65-69).  The satellite cells undergo at least one mitotic cycle, after which some of them 
differentiate into myoblast-like cells (59, 66, 70-72).  These new myoblasts can serve 
to help the injured myofibre in one of two ways: 1) the myoblasts can fuse with each 
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other to form new fibres or 2) the myoblasts can join the surviving myofibres of the 
damaged tissue (59, 66, 73-75).  IGF-1 may play a role in this repair process due to its 
presence in the cytoplasm of myoblasts, myotubes, and satellite cells during the 
regeneration process (59, 76, 77).  Thus, the increased load imposed by resistance 
training stimulates the active muscle to produce IGF-1 which, in turn, initiate the 
satellite cell-derived myoblasts.  The myoblasts then fuse with existing myofibres (59, 
79-83).  This fusion provides additional myonuclei to the muscle, indicating an 
increase in muscle mass (59, 82, 84-88).   
 
The finding of reduced IGF-1 with (ultra) endurance exercise may be related to an 
exercise induced energy deficit.  Decreases in body weight/fat mass and decreases in 
IGF-1 have been observed as a result of restricted energy intake in military personnel 
during eight days of simulated field operations (201).  This is in line with previous 
literature demonstrating that IGF-1 plasma levels are regulated by nutrient intake (8).  
A reduction in caloric intake by 50% will produce a significant decrease in IGF-1 (8, 9).  
This reduction is due to a decrease in IGF-1 gene transcription.  A reduction of protein 
intake as small as 25% will produce an equivalent decrease in IGF-1 by regulating 
mRNA stability and translation (8).  While these associations have been observed 
cross-sectionally (190) and over the course of 4 to 8 days in intervention studies 
(201), it is plausible that decreases in IGF-1 concentration may also occur acutely due 
to a possible negative energy or protein balance created by a single bout of endurance 
exercise.  Since longer duration exercise may increase the likelihood of incurring an 
acute energy or protein deficit, we performed a subgroup analysis based on duration 
of exercise but the heterogeneity was high.  In an attempt to explain the source of 
heterogeneity the duration of exercise subgroups were further separated by type of 
exercise, but this created subgroups that were too small for comparison. 
 
5.4.1 Strengths and Limitations 
Despite the studies in our meta-analyses being split into subgroups by type of 
exercise, the heterogeneity in many of these subgroups remained high (I2> 50%).  In 
order to determine the source of heterogeneity studies were grouped according to 
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mode and duration of exercise (neither of which resulted in a decrease in 
heterogeneity).  We conclude that the source of heterogeneity is inherent to the 
individual study designs.  Therefore, in subgroups where heterogeneity is high, there 
is a need for appropriately powered and randomised studies utilising consistent 
exercise protocols (duration, mode, and type of exercise).  In addition, our research 
focused on total IGF-1 and does not take into account the IGF-1 binding proteins.  
Future research investigating the effects of free IGF-1 binding proteins and/or free 
IGF-1 may provide more insight into how much IGF-1 is being produced and how 
much is biologically active.  Given previous research indicating that diet can impact 
IGF-1 concentration (153, 155, 157), and the fact that most of the studies utilised did 
not mention a dietary control, it is possible that participant’s diets may have impacted 
the results.  Furthermore, we cannot discount the potential effect of the 60 studies 
that were not able to be included in the meta-analysis.  However, it appears that the 
direction of effect of these studies is largely consistent with the effects found in the 
subgroups of our meta-analysis.  It is, therefore, likely that inclusion of these 
additional studies may change the magnitude of the effect estimate it is unlikely that it 
will influence the direction of effect. Given the high volume of studies that were unable 
to be included in this meta-analysis we would like to stress the importance of future 
studies reporting their data in a manner which facilitates inclusion in meta-analyses.  
The main strength of the present review is that it provides the first systematic review 
and quantitative estimate of the association between exercise and IGF-1 
concentration; it clearly indicates that some of the ambiguity in the literature is due to 
the differential effect type of exercise has on the response of IGF-1 to an exercise 
stimulus. 
Section 5.5 Conclusion 
The results of these meta-analyses provide evidence indicating that the association 
between exercise and IGF-1 is dependent upon the type of exercise. Our results serve 
to guide individuals seeking increased IGF-1 concentration for the purpose of 
increasing muscle mass towards resistance exercise, while people interested in 
lowering their IGF-1 concentration may wish to preferentially select endurance 
exercise.     
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6. EXERCISE, DIETARY PROTEIN, AND COMBINED EFFECT ON IGF-1 
Section 6.1 Introduction 
 
Factors that are thought to mediate blood IGF-1 concentration include dietary protein 
(202, 203) and exercise (202, 203).  Cross sectional studies have shown that chronic 
elevations in dietary protein are associated with increased IGF-1 concentration (151) 
and increased cancer risk (124, 204).  However, no study has tracked the acute IGF-1 
response to a single dose of dietary protein.  While numerous studies have examined 
the effect of exercise on IGF-1 concentration (156, 159), the results appear to be 
contingent upon exercise type i.e. with resistance (205, 206) and sprint (207) 
exercises elevating IGF-1 concentration and endurance exercise (208, 209) decreasing 
IGF-1 concentration.  Studies investigating the acute IGF-1 response to the combined 
effect of exercise and protein ingestion have predominantly used resistance exercise 
(210, 211) or endurance running (212) and have failed to show significant changes in 
IGF-1 concentration, indicating a possible interaction effect between protein and 
exercise.   Furthermore, there are no studies that have investigated the effects of all 
three conditions (protein, exercise and protein with exercise) in the same individuals.   
 
The present study was designed to better understand the impact a single dose of 
protein and exercise can have on IGF-1 and, specifically, if exercise modulates any 
protein-induced increase in IGF-1 concertation.  Therefore, the purpose of this study 
was to analyse acute effects of dietary protein and exercise, independently and 
combined, on free IGF-1 concentration and the time-course thereof.   
 
 
Section 6.2 Methods 
6.2.1 Participants 
Participants were recruited locally via flyers, social media postings and Otago 
University email lists.  Inclusion criteria required all eligible participants to be aged 
between 18 and 65 y and be capable of participating in physical activity as indicated 
by a Physical Activity Readiness Questionnaire.  In addition, all participants were 
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healthy, not on medication (other than birth control pills or vitamins/minerals), not 
diabetic nor in any identifiable disease state, BMI<30, not pregnant or lactating nor 
planning pregnancy.  A CONSORT diagram detailing the progress of all recruited 
participants is displayed in Figure 8.  Participant characteristics for all participants 
that completed the study are detailed in Table 7. 







Table 7: Exercise, Dietary Protein, and Combined Effect on IGF-1 
participant characteristics (n=24; m=13, f=11) 
Age (year) 24.9 ± 4.6 
Height (cm) 173.9 ± 10.6 
Body mass (kg) 71.9 ± 12.6 
Body fat (%) 18.5 ± 8.4 
VO2max (ml/kg/min) 47.0 ± 9.9 
Values are means ± SD 
 
6.2.2 Experimental Design 
This randomised, three-way crossover study was performed in Dunedin, New Zealand 
between January and March 2019.  Trials were conducted at the same time of day for 
each participant, separated by a minimum of one week, and maximum of 17 days 
(mdn = 7 days).  The three conditions consisted of: (1) a high protein (42 g) meal; (2) 
exercise (20 min with four 30 second sprints); and (3) exercise followed by a high 
protein meal.  Participants were randomly assigned to complete the three conditions 
in one of six possible orders via a random number generator (Microsoft Excel for 
Office 365 MSO 16.0).  The trials were not blinded; however, participants were not 
told the condition in which they participated until they reported to the facility the 
morning of testing and the subsequent analysis of the samples was blinded.  The study 
was approved by the University of Otago Ethics Committee (H18/133), conformed to 
the standards set by the Declaration of Helsinki, and written informed consent was 
obtained from all participants.  The study was registered with the Australian New 
Zealand Clinical Trials Registry (ACTRN12618001919202p).   
 
6.2.3 Pre-Condition Testing  
After providing written informed consent, and at least one week prior to participating 
in the first condition, anthropometric measurements, bio-electrical impedance 
analysis (BIA; InBody230 GBC BioMed, Auckland, N.Z.) for body composition, and a 
maximal oxygen capacity (VO2max) test were conducted.  Participants completed the 
Physical Activity Readiness Questionnaire (PAR-Q) to assess suitability to perform 
maximal exercise, and an exercise history questionnaire to determine the amount of 
exercise they have been performing in the three months preceding the experiment.  
No one was excluded based on the results of the PAR-Q.  The VO2max test was 
performed on a cycle ergometer (Velotron, Seattle WA, USA) via a modified Andersen 
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protocol (213) and was used to set the workload for the exercise condition of the 
study as well as to detect the training status of the participants (213).     
 
6.2.4 Experimental Conditions 
Protein Condition 
Participants reported to the testing facility in the morning after a 10 h overnight fast.  
Participants confirmed that they did not perform exercise for 24 h prior to testing and 
body composition was assessed using BIA.  Thirty min after the baseline assessment 
point (the first blood sample) (Figure 9), participants were immediately handed a 
high-protein liquid meal (whey protein isolate and dextrose mixed in almond milk) to 
consume within 10 min. The high-protein meal provided 45 g of protein, 28 g of 
carbohydrate, and 12 g of fat, totalling 1707 kJ.  After consuming the high-protein 
meal participants rested quietly for the remainder of the session, consuming only 
water. At the completion of the session, participants were provided with a meal 
consisting of mini pizzas (or allergen-free equivalent) (1410 kJ, 14.2 g protein, 7.8 g 
fat, and 50.9 g carbohydrates per pizza), which they consumed ad libitum at the 
completion of the first condition.  The number of pizzas consumed was then replicated 
after the participants’ second and third sessions.  The pizzas served to control another 
meal for the participants and insure that they did not leave the lab hungry or at risk of 
low blood glucose.  Participants left the facility and were instructed to refrain from 
physical activity until after they had returned to the facility for their final blood draw 
of the condition, which was conducted 24 h after the initial session began.  Specifically, 
participants reported to the facility, after fasting for 10 h, for a blood draw that was 
conducted 24 h after baseline.      
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Figure 9:  Exercise, Dietary Protein, and Combined Effect on IGF-1 Protocol: P= protein meal, C= isocaloric placebo meal, = blood draw, = seated and 




The protocol was the same as in the protein condition, however, instead of resting 
quietly prior to consuming the meal, participants performed a 20-min exercise session 
on a cycle ergometer consisting of four cycles of: 4 min at 15% of aerobic threshold 
power followed by 30 s of maximum effort at 100% of aerobic threshold power.  The 
protocol was based upon previous research using high intensity interval exercise 
and/or 30 second maximal effort sprints, which inducted a significant change in IGF-1 
concentration (214).  By using a similar protocol to previous studies, it was likely that 
the intensity of the exercise was high enough to produce an IGF-1 response.  Upon 
completion of the exercise, participants received an isocaloric low-protein liquid meal, 
which they were instructed to consume within 10 min.  The low-protein meal 
consisted of: dextrose and cocoa powder mixed in almond milk (1657 kJ, 65 g 
carbohydrate, 5.9 g protein, 11.6 g fat).   
 
Protein and Exercise Condition 
The protocol was the same as in the exercise condition.  However, exercise was 
followed by consumption of the high-protein liquid meal instead of the low-protein 
meal (compositions as noted in prior sections).   
3.  
6.2.5 Blood Collection  
A venous cannula (BD Adsyte Pro 20 GA 61 mL/min, Sandy, Ut) was inserted into the 
antecubital vein approximately 10 min after the participant arrived for testing.  Blood 
samples were collected at rest, immediately after rest or within five min of concluding 
exercise (depending on the condition), and at regular intervals during the recovery 
period (Figure 9).  Samples were collected from the cannula into syringes and 
immediately transferred to EDTA vacutainer tubes (K2E 10.8mg, Plymouth, UK), 
inverted 8 times, refrigerated, and within an hour of collection, centrifuged at 2000 g 
for 10 min (Digisystem Laboratory Instruments Inc., Table Top Centrifuge, New Taipei 
City, TW).  Plasma was aliquoted into two microcentrifuge tubes (1.5 mL) and frozen 
at -80◦C until later analysis.  The cannula was removed after the five h of testing.  The 
fasted 24 h blood samples were collected into EDTA vacutainer tubes (K2E 10.8 mg, 
Plymouth, UK), which were treated and processed in the same manner as above. 
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6.2.6 Analytical Methods 
Free IGF-1 concentration was measured using commercially available enzyme-linked 
immunosorbent assays (ab211651 Human IGF1 SimpleStep ELISA Kit, Cambridge, 
UK).  Absorbance was read on a microplate reader at 450 nm (BioRad Model680, 
Hercules, CA).  All analyses were performed in duplicate, and all analyses for each 
participant were performed within the same assay batch to reduce inter-assay 
variance in compliance with recommended laboratory procedures (215).  The intra-
assay variance was 15.2%.  The assay minimal detectable dose sensitivity was 11 
pg/mL.   
 
6.2.7 Statistical Analysis 
Data are expressed as mean ± SD.  Data were analysed using STATA statistical 
software (STATA IC 15, College Station, TX, USA).  A P<0.05 was considered 
statistically significant.   
 
A sample size of 24 participants was chosen to provide 80% power to detect a 
treatment effect of a 0.5 standard deviation difference in mean IGF-1 area under the 
curve (AUC) response, assuming a within participant correlation of 0.7 and an alpha of 
0.05 (216).  Total AUC was calculated by trapezoidal reconstruction for the time 
period between baseline and 300 min (i.e. total duration of a session). Differences in 
area under the curve between conditions was calculated by a within subject repeated 
measures analysis of variance (ANOVA).  A within subject repeated measures ANOVA 
was also used to detect between condition difference in: baseline IGF-1 concentration, 
incremental AUC, peak IGF-1 concentration, time of peak concentration, IGF-1 
concentration at 24 h, and change in IGF-1 concentration from baseline to peak.   
 
A multilevel mixed-effects linear regression was run to investigate the change in IGF-1 
concentration over time for all three conditions.  Tests of simple main effects were run 




A separate multilevel mixed-effects linear regression was utilised to investigate 
potential differences between the baseline measure and 24 h after baseline in each 
condition.  Tests of simple main effects were conducted to determine if IGF-1 
concentration at 24 h after baseline was significantly different from baseline in each 
condition.   
 
Section 6.3 Results 
Twenty-four recreationally active males and females completed the study.  The 
characteristics of these participants are presented in Table 7.  Participants that could 
not complete the study were excluded from the analysis.  Reasons for the dropouts 
included: scheduling conflicts due to the time commitment necessary to complete the 
study (four), fainting when the cannula was inserted into their arm or being 
uncomfortable with blood draws (five), inability to find a suitable vein for cannulation 
(one), or family emergency (one).  An unpaired t-test was conducted to investigate 
whether there were differences in demographic characteristics between those who 
completed the study and those who did not.  There were no differences in 
demographics between those that completed the study and those who did not (Table 
8).  
  
Table 8: Exercise, Dietary Protein, and Combined Effect on IGF-1 T-Test to 
investigate potential dropout bias 
 
Variable Mean ± SD for Included 
Participants 
Mean ± SD for Excluded 
Participants 
P-Value 
Sex 13 M/11 F 4 M/7 F 0.34 
Age (y) 24.9 ± 4.6 22.3 ± 3.8 0.10 
Height (cm) 173.9 ± 10.6 171.2 ± 7.8 0.46 
Body mass (kg) 71.9 ± 12.6 70.6 ± 12.3 0.46 
Body fat (%) 18.5 ± 8.4 17.8 ± 6.3 0.99 
VO2max (ml/kg/min) 47.0 ± 9.9 47.2 ± 10.1 0.96 
Max heart rate (bpm) 181.7 ± 13.7 189.7 ± 6.4 0.07 
Max power (W) 244.8 ± 67.2 245.5 ± 71.4 0.98 





6.3.1 Changes in IGF-1 Concentration over Time 
In the protein condition, IGF-1 concentration did not change over the first 300 min 
(p=0.56).  However, at 24 h IGF-1 concentration was 3.41 pg/mL higher (95% CI 0.64 
to 6.07; p=0.02) than at baseline (Figure 10).   
 
Figure 10: Exercise, Dietary Protein, and Combined Effect on IGF-1: Mean free IGF-1 concentration 
(pg/mL) from fasted, morning baseline through 300 min after baseline and next morning fasted IGF-1 
concentration (1440 min).  * significant change from baseline free IGF-1 concentration     
 
In the exercise condition IGF-1 concentration was significantly higher at 30 min 
(immediately after exercise) (Δ 0.41 pmol/L; 95% CI 0.05 to 0.77; p=0.04) (Figure 10).  
At none of the other timepoints was IGF-1 different from baseline (including at 24 h (Δ 
0.35 pmol/L; 95% CI 0.34 to 0.35; p=0.69)).  
In the exercise and protein condition IGF-1 concentration did not change over time 
(first 300 min p=0.712) or from baseline to 24 h (Δ 0.21 pmol/L; 95% CI 0.21 to 0.22; 
p=0.391).  
6.3.2 Differences between Conditions 
The plasma IGF-1 AUC was not significantly different between conditions (p=0.69).  
The baseline IGF-1 concentration (p=0.93), peak concentration (p=0.88), change from 
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baseline to peak concentration (p=0.37), and change from baseline to 24 h 
concentration (p=0.63) were not statistically significant between conditions.  The 
difference in IGF-1 concentration at 24 h between conditions approached significance 
(p=0.07).  The time to peak concentration within the first 300 min was significantly 
longer in the protein condition than the exercise condition (85.00 ± 34.64 min; 
p=0.01) and the protein with exercise condition (66.41 ± 35.63 min; p=0.04).  The 
time to peak concentration was similar in the protein with exercise and exercise only 
conditions (p=0.51). 
6.4 Discussion  
To our knowledge, our study is the first to show that IGF-1 concentration is increased 
24 h after ingesting protein (45 g).  We also observed an increase in IGF-1 
concentration immediately following high-intensity interval cycling, which is similar 
to that observed with previous research, indicating such exercise produces elevations 
in IGF-1 concentration immediately after exercise (217, 218).  Interestingly, when 
exercise preceded protein ingestion no increase in IGF-1 concentration at 24 h was 
observed.   
When analysing the differences between conditions for summary measures, the AUC 
was similar in all three conditions.  However, the shapes of the IGF-1 concentration 
response curves were different (Figure 10).  Therefore, it is possible that the different 
stimuli elicit different release mechanisms or a change in the sensitivity.  The 
mechanisms through which dietary protein affects free IGF-1 concentration have yet 
to be fully elucidated.  However, studies investigating the effects of consecutive days 
of high protein diets have shown IGF-1 to increase linearly with protein dose (219).  
Interestingly, our results indicate no significant changes in IGF-1 concentration for up 
to 5 hours after ingestion, but a significant, increase at 24 h.  It is possible that the 
hepatic release of IGF-1 is a slow process and any rise in IGF-1 caused by dietary 
protein may not be immediately observed in the circulation.  In addition, we cannot 
discount the possibility that our choice to substitute a high protein meal with an 
isocaloric high carbohydrate meal influenced the results since both insulin and IGF-1 
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share the PI3K signalling pathway (183).  However, given the known impact of a 
negative energy balance on IGF-1 concentration (59), the study was designed to match 
the conditions for energy rather than carbohydrate, and it is impossible to vary 
protein content and match both energy and other macronutrients.  Furthermore, the 
study design utilised a liquid whey protein meal due to the increased speed of gastric 
emptying that occurs with liquid meals (220) and that fast rate of absorption of whey 
protein (221).  In this way, changes in IGF-1 concentration may occur faster with a 
liquid meal than a solid meal.  The liquid meal also provided an allergen free meal that 
is easy to make palatable for all participants. However, it is likely that ingestion of a 
solid meal (which is likely more representative of everyday practices) with a different 
protein type (e.g. soy, casein, etc.) would slow the rate of gastric emptying and delay 
the IGF-1 response (221).  
The mechanisms underlying the release of IGF-1 after exercise are not fully 
understood.  However, there are three leading theories(200) : 1) exercise increases 
growth hormone secretion, which results in increased hepatic production of IGF-1 and 
circulating IGF-1(198); 2) growth hormone secretion stimulated by exercise induces 
endogenous production of IGF-1 by the muscle; 3) exercise stimulates the active 
muscle to produce IGF-1 independently of circulating growth hormone(195).  Thus, 
differences in the time course response of IGF-1 concentration between our 
experimental conditions may be due to independent regulatory mechanisms 
associated with protein consumption and exercise.  However, the mechanisms of IGF-
1 release were not part of our investigation.   
The most novel finding of our study is that IGF-1 concentration was still significantly 
greater 24 h after ingesting protein than at baseline.  This increase has not been 
observed previously and may be indicative of a delayed effect caused by the 
consumption of protein.  Since the half-life of IGF-1 is six h (222) and the stability of 
IGF-1 concentration can increase due to binding proteins (222), it is possible that 
dietary protein consumption causes changes in circulating IGF-1 by creating a 
complex with binding protein and extending the half-life to 15 h (222).  Regrettably, 
we were unable to assess IGF binding proteins. The change in IGF-1 concentration 24 
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h after protein ingestion may have implications for long term IGF-1 regulation.  Since 
an elevation was seen with a single high protein meal, it is possible that multiple high 
protein meals on a consistent basis may chronically or repeatedly elevate IGF-1 
concentration. Future research should address this supposition and determine the 
validity of our speculation.   
It should be noted that we chose to monitor IGF-1 concentration for five h after 
baseline and at one time point 24 h after baseline.  These time points were chosen in 
order to monitor the IGF-1 response immediately following protein ingestion, where 
we would have expected to see the most change.  We used the 24 h measure to reduce 
any potential effects of circadian IGF-1 release and reveal how the effects of each 
condition altered the fasted, morning IGF-1 concentration.  Thus, we feel any change 
observed in IGF-1 was due to the condition and not the timing of sampling.    
The observed effects of exercise on IGF-1 concentration, are in agreement with others 
who conducted two thirty second sprints on a cycle ergometer with four min recovery 
between sprints (223), demonstrating that high-intensity exercise acutely elevates 
IGF-1 concentration (224).  Part of this observed response may be due to plasma 
volume shifts.  Plasma volume shifts occur during the onset of exercise due to osmotic 
movement of water from the intravascular space to the active muscle (225).   We did 
not measure haematocrit (nor haemoglobin) and thus do not know the magnitude of 
the haemoconcentration.  However, we did measure an increase in IGF-1 
concentration immediately after exercise of 16 percent and based upon the observed 
haemoconcentration with this type of exercise, ~2 percent as reported by others 
(223), we feel confident to conclude that the post-exercise rise in IGF-1 was in 
response to the exercise bout and not solely haemoconcentration.  Moreover, as free 
IGF-1 should move with the plasma out of the vascular space, any effect of plasma 
volume shifts should not affect the observed concentration in reflecting IGF-1 release 
(226). Furthermore, the physiological influence of hormones on target tissue 
receptors is affected by concentration change, regardless of the mechanism by which 
that change is implemented (227).   
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Despite an acute transient increase in IGF-1, exercise appears not to result in any 
lasting changes in IGF-1, as the concentration measured at 24 h was not different from 
baseline.  This is consistent with several other previous studies that also found no 
change the morning after a 36 km run(208), one hour of single-leg kicking (in 
men(228) and women in both the luteal and follicular phase(229)), moderate 
duration resistance exercise(230), long duration resistance exercise(230), moderate 
duration cycling(230), and long duration cycling(230).  However, it is possible that 
when exercise induces a large energy deficit, decreases in IGF-1 concentration can 
occur since reductions in IGF-1 24 h after an ultra-endurance race have been observed 
in male participants (231).  In addition,  decreases in body weight/fat mass and 
decreases in IGF-1 have been observed as a result of restricted energy intake in 
military personnel during simulated field operations (201).   
Previous studies have investigated the relationship between protein consumed 
immediately after exercise and IGF-1. However, most of these studies involved 
resistance exercise (210, 211) or endurance running (212, 232) and failed to find a 
significant effect of protein with exercise on IGF-1 concentration.  Our study is the first 
to monitor the effects of dietary protein with intermittent high-intensity sprint cycling 
exercise.  Our results indicate that the combination of dietary protein and exercise 
dose not result in any statistically significant change in IGF-1 concentration over time.  
This is a surprising result given that dietary protein is often proclaimed, when 
combined with exercise, as a means to increase skeletal muscle mass.  Thus, we would 
have expected exercise and dietary protein to have an additive effect on IGF-1 
concentration. This was not the case; but it is possible that under different conditions 
it may have occurred.  Since no such additive effect was observed with our protocol, 
further research is needed to determine the optimal conditions (timing, dose, type of 
protein) for protein supplementation after exercise to enhance IGF-1 and protein 
synthesis. 
When protein ingestion was preceded by exercise there was no effect on IGF-1 the 
following morning.  The effect of exercise on protein induced IGF-1 release may be 
indicative of a protective mechanism produced by exercise in which IGF-1 
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concentration returns to baseline faster.  It is possible that an exercise induced 
increase in IGF-1 binding proteins reduced the quantity of free IGF-1 in circulation 
(233).  However, without measuring the concentration of IGF-1 binding proteins we 
are unable to confirm this theory.  To our knowledge, this is the first study with a 
subsequent 24 h, measure to investigate the effects of exercise with protein on IGF-1.  
An additive, or perhaps synergistic, effect when protein ingestion was preceded by 
exercise could have been expected.  That is, specifically showing a significant increase 
after exercise (due to stimulator actions of the physical activity and plausible localised 
IGF-1 release) as well as at 24 h (due to the previously observed 24 h increase in the 
protein condition and plausible systemic IGF-1 release).  Surprisingly, this was not 
observed.  The total lack of response suggests a potential antagonism action exists 
from the interaction of protein ingestion and exercise (i.e., as manipulated in this 
study).  We cannot explain why such an action would occur, but it could represent pre- 
or post-secretion regulatory events that control IGF-1 levels in the circulation and 
maintain homeostasis.  Future research needs to pursue this interesting finding and 
elucidate the mechanism(s).  
Section 6.5 Conclusion 
Our results demonstrate that the timing and magnitude of plasma free IGF-1 
concentration are influenced differently by exercise, than with protein ingestion, or 
when protein ingestion is preceded by exercise.  Our results are the first to describe 
the time course response of free IGF-1 to dietary protein.  While all three conditions 
resulted in a similar area under the curve for IGF-1 concentration, the timing and 
magnitude of change in IGF-1 concentration were different.  Dietary protein did not 
produce significant changes in IGF-1 concentration in the initial 5 h after ingestion, 
but it did significantly increase IGF-1 concentration 24 h after baseline.   We observed 
the time course response of IGF-1 concentration to a single bout of intermittent sprint 
exercise followed by protein ingestion.  This condition, exercise with protein, is most 
applicable to athletic populations seeking to maximise skeletal muscle growth by the 
consumption of protein directly after a workout.  The 24 h increase in IGF-1 produced 
by dietary protein alone was mitigated by performing exercise with protein.  This 
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finding may be important for the long-term health of athletes or individuals on a high 
protein diet.  Since it appears that exercise prior to protein ingestion provides a 
protective mechanism it may be possible to mitigate the harmful effects of a high 
protein diet with exercise. This enhanced knowledge of the time course of effects of 
protein and exercise on IGF-1 concentration has implications for individuals wanting 















7. PHYSICAL ACTIVITY, DIETARY PROTEIN AND INSULIN-LIKE GROWTH 
FACTOR 1: CROSS-SECTIONAL ANALYSIS UTILISING UK BIOBANK 
Section 7.1 Introduction  
Insulin-like growth factor-I (IGF-1) is an anabolic hormone that stimulates cell growth 
and cell division (42, 43).  The effects of IGF-1 may be beneficial or detrimental for 
human health and well-being.  IGF-1 is beneficial in terms of muscle growth and repair 
(214, 234-236).  However, higher circulating concentrations of  IGF-1 are associated 
with increased  risk of several types of cancer and mortality (190, 237-239), likely due 
to an over stimulation of cell replication and inhibition of apoptosis, thereby, 
increasing the likelihood of mutations occurring (237).  Given the diverging effects of 
IGF-1, discerning the factors that modulate its concentration may provide insight into 
how to optimize the beneficial effects of IGF-1 while mitigating deleterious outcomes. 
Several factors such as age (240), height (241), diet (151), and physical activity (217) 
have been shown to be associated with IGF-1 concentration.  While age and height are 
non-modifiable variables, diet and physical activity can be changed through 
behaviour.  Previous cross-sectional studies, including up to 4,201 participants, that 
investigated the effects of diet on circulating IGF-1 concentration, have found higher 
dietary protein to be positively associated with circulating IGF-1 concentration with 
magnitudes of effect ranging from 0.01 to 0.11 nmol/L of IGF-1 for every 1 g of dietary 
protein (151, 152, 166).  Cross-sectional studies have also indicated calcium intake to 
be positively associated with circulating IGF-1 concentration (151, 166).  Calcium is 
highly correlated with dairy protein – normally a large component of total protein 
intake – and it is difficult to disentangle the associations of total protein, dairy protein 
and calcium intakes with circulating IGF-I concentrations (151).  Other dietary 
nutrients have either been inconsistently associated with circulating IGF-1 
concentration (e.g. fibre (151) and monounsaturated fat (151)) or not at all associated 
with circulating IGF-1 concentration (e.g. total fat, saturated fat, and polyunsaturated 
fat) (151, 176, 242, 243).   The UK Biobank dataset provides the opportunity to 
investigate the association between protein and circulating IGF-1 in the largest sample 
of participants to date (151, 152, 166, 168, 171).   
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While there is a large body of research on the topic of physical activity and circulating 
IGF-1 concentrations, the results are inconsistent (205, 208, 223, 244, 245).  These 
inconsistent results have been, at least in part, explained by a recent meta-analysis of 
intervention studies, which indicated that the association between physical activity 
and circulating IGF-1 concentration is dependent upon the type of exercise (246).             
Our study will provide further evidence to help clarify the inconsistencies in the 
research by not only analysing each of these associations independently (dietary 
protein vs circulating IGF-1 concentration and physical activity vs circulating IGF-1 
concentration) with a large sample size, but will also determine if/how physical 
activity affects the positive association between dietary protein and circulating IGF-1 
concentration in healthy adults.  Examining the influence of physical activity on the 
relationship between dietary protein and circulating IGF-1 may help determine if the 
association between dietary protein and circulating IGF-1 is different in those who are 
physically active versus those less active.  By being the first study to assess if/how 
physical activity affects the relationship between dietary protein and circulating IGF-1 
we will not only provide evidence to help clarify the inconsistencies in the current 
research, but also aid in guiding future research. 
Section 7.2 Methods 
7.2.1 Study Design and Participants 
UK Biobank is a prospective cohort study comprising 502,543 individuals recruited 
from across the UK between 2006 and 2010 (247).  The study protocol is available 
online (248).  In brief, participants who were between 40 and 69 y and living within 
25 mi from 1 of 22 assessment centres were identified from National Health Service 
patient registers and invited to attend a local assessment centre for participation in 
UK Biobank.  At the assessment centre participants gave informed consent to 
participate in the UK Biobank via a signature capture device and completed a 
touchscreen questionnaire, answering questions related to sociodemographic 
characteristics, diet, lifestyle, reproductive, and environmental factors (249).  
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Approval was obtained from the North West Research Ethics Committee 
(06/MRE08/65) in accordance with the principles of the Declaration of Helsinki.    
7.2.2 Dietary Assessment 
In April 2009, an amendment was made to the protocol in which all new participants 
completed a web-based 24 h dietary assessment tool at their initial visit (250).  This 
additional assessment was completed by the least 70,000 participants recruited for 
the study.  The web-based 24 h dietary assessment was also emailed, to all 
participants who provided the UK Biobank with an email address, once every 3 to 4 
months for a total of four times between February 2011 and June 2012 (251).  In total 
175,402 participants completed at least one online 24 h dietary assessment and 
60,677 participants completed at least two dietary assessments.  The assessment asks 
participants to select the food they consumed within the previous 24 h from a list of 
206 types of foods and 32 types of drinks.  Portion sizes for each item were specified 
and participants selected how many portions they consumed.  For most items, a 
specific portion size was used (e.g. 1 apple, 1 slice of ham); for other items (such as 
pasta and rice) the portion size was specified as a ‘serving’. The mean daily intakes of 
nutrients for each food/drink was calculated by multiplying the frequency of 
consumption by a standard portion size and the nutrient composition of that specific 
item.  Spearman’s correlation coefficients for estimates of the majority of nutrients 
ranged from 0.5 to 0.9 (mean= 0.6), when comparing the web-based 24 h assessment 
(206 types of foods and 32 types of drinks) with an interviewer-administered 24 h 
recall completed on the same day (252).     
7.2.3 Physical Activity Assessment 
Physical activity was assessed via the UK Biobank touchscreen questionnaire, based 
upon the International Physical Activity Questionnaire (IPAQ) and designed to 
estimate metabolic equivalents (MET) h/week and leisure time (253).  Participants 
were asked to indicate the number of days in a typical week they participated in either 
walking, moderate physical activity, or vigorous physical activity for a duration for 10 
min or more.  Participants were then asked how many min per day they performed 
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each activity.  In order to generate the min of activity per week, the number of days 
active was multiplied by the number of min/day for each of the categories (walking, 
moderate physical activity and vigorous physical activity).  Responses indicating that 
an activity was performed for more than 1260 min/week were curtailed at 1260 min 
in accordance with the guidelines for data processing and analysis of the IPAQ (254).    
In order to represent energy expenditure, excess MET values were calculated by 
subtracting one MET from the value of each activity.  In this way, excess MET 
represents the energy expenditure above that of an inactive person (255).  The excess 
MET value for each activity was multiplied by the duration of activity (h/week) to 
obtain the total excess MET-hours per week.  Categorization of low physical activity 
corresponds to less than 10 h of physical activity per week, “moderate” corresponds 
with 10 to 50 h per week, and “high” corresponds with more than 50 h of physical 
activity per week.   
7.2.4 IGF-1 Measurement 
A series of biological samples were collected during participant recruitment and the 
first repeat assessment, one of which involved collecting approximately 45 ml of 
blood.  A total of 36 biochemical markers were selected for assay in all participants 
that donated blood.  Between 2006 and 2010, at their initial visit, a total of 467,041 
participants donated blood and had it analysed for total serum IGF-1 concentration 
(nmol/L).  Between 2012 and 2013, at their first repeat assessment visit, 17,699 
participants had their blood analysed for IGF-1 concentration.  Total serum IGF-1 was 
measured by CLIA analysis on a DiaSorin Ltd, LIASON XL (256).  Within lab total 
coefficient of variation (CV) was calculated separately for each of the three internal 
quality control (IQC) levels (IQC level low= 7.06 to 12.84, IQC level medium= 27.23 to 
44.97, IQC level high= 35.85 to 84.62) (257).  The within lab total CV was 6.03% for 
the low IQC level, 5.29% for medium, and 6.18% for the high IQC level (257).  
7.2.5 Exclusions 
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Participants were excluded from the analyses if they declared a history of long-
standing illness, disability or infirmity.  Individuals were excluded if they were taking 
medication for: cholesterol, blood pressure, diabetes or exogenous hormones.  
Diabetics were excluded from the analysis.  Participants with a physical activity level 
greater than 6720 min per week were excluded, based on the IPAQ recommendations 
for data cleaning and processing (254).  Dietary assessment records with an energy 
intake greater than the pre-specified sex-specific limits (20,000 kJ for men and 18,000 
kJ for women) were excluded (258).  Participants who completed less than two 24 h 
dietary recall questionnaires were excluded from the analysis in order to obtain a 
measure that was more representative of their usual diet.  Individuals that were 
missing an IGF-1 measure were also excluded from the analyses.  
7.2.6 Statistics 
Multiple linear regression was used to assess the association between dietary protein 
and/or physical activity on serum IGF-1 concentration.  Initially, three simple 
regression models were fitted.  The first model examined the relationship between 
dietary protein (g/day) and serum IGF-1 concentration (nmol/L).  The second model 
investigated the relationship between physical activity (h/week) and serum IGF-1 
concentration (nmol/L).  The third model included both dietary protein (g/day) and 
physical activity (h/week) to investigate the influence of each variable on the other.  
Analogous, fully adjusted models were examined which included protein and physical 
activity with adjustments made for sex, age (at time of recruitment), smoking status, 
body mass index (BMI), alcohol intake (g/day), energy intake (kJ/day), carbohydrate 
intake (g/day), fibre (g/day), and calcium (mg/day) (data not shown for fully adjusted 
models of dietary protein and IGF-1 concentration as well as physical activity and IGF-
1 concentration).  Previous literature has shown that IGF-1 concentrations differ by 
sex ) (28).  However, there is no literature to support that the response of IGF-1 
concentration to dietary protein and/or exercise varies by sex.  Therefore, the 
statistical model was adjusted for sex, as opposed to running separate models for each 
sex.  Residuals were checked in all regressions and there was no evidence of a 
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violation of any assumptions.  The statistical package Stata V.16 (StataCorp LP, College 
Station, Texas, USA) was used for all analyses. 
Section 7.3 Results 
Our dataset obtained from UK Biobank originally included 502,543 participants. 
Participants were excluded from these analyses if they declared a history of long-
standing illness, disability or infirmity (n= 159,912).  Individuals were excluded if they 
were taking medication for: cholesterol, blood pressure, diabetes or exogenous 
hormones (n= 84,486).  Diabetics were excluded from the analysis (n= 26,402).  
Participants with a physical activity level greater than 6720 min per week were 
excluded (n= 17,708).  Dietary assessment records with an energy intake greater than 
the pre-specified sex-specific limits (20,000 kJ for men and 18,000 kJ for women) 
were excluded (n= 292,650) (258).  Participants who completed less than two 24 h 
dietary recall questionnaires were excluded from the analysis (n=356,666).  
Individuals that were missing an IGF-1 measure (n= 35,477) were also excluded from 
the analyses.  Descriptive characteristics for the 60,677 participants that met the 
inclusion criteria are displayed in Table 9.   
Table 9: Cross Sectional Participant Characteristics, N=60,677 







Height (cm)*  170.5 (9.1) 
BMI (kg/m2) * 26.1 (4.0) 
Alcohol intake (g/day) *(12,984 have an individual 
mean of 0.) 
17.6 (19.5) 
Smoking status 









Menopausal status (women only.  One man recorded 
they had not been through menopause) 
Yes, had menopause ᵻ 
No, did not have menopause ᵻ 
Not sure- had hysterectomy ᵻ 
Not sure- other reason ᵻ 








Dietary intake: Energy (kJ) *  8,920.9 (2206.4) 
Dietary intake: Protein (g) *  82.6 (21.1) 
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Dietary intake: Protein per body mass (g/kg) * (49 
people responded with two or more protein 
measures but did not provide their weight.) 
1.11 (0.32) 
Dietary intake: Fat (g) * (WebQ_fat_1_0, to be 
provided) 
78.9 (25.0) 
Dietary intake: Carbohydrate (g) *  255.0 (73.1) 
Dietary intake: Fibre (g) *  16.5 (5.7) 
Dietary intake: Calcium (mg) *  980.1 (314.5) 
Physical activity (min/week) * (115,728 have not 
answered this, 8,123 had 0 minutes per week) 
1177.1 (1167.8, 1186.6) 
Physical activity 
Low (<10 excess MET h per week),  
Moderate (>=10 and < 50 excess MET h per week),  





Total IGF-1 concentration (Nmol/L) ‡ 21.66 (21.62,21.70) 
* mean (SD)  
ᵻ n (%) 
‡ geometric means (95% confidence intervals) 
 
The change in serum IGF-1 concentration (nmol/L) per unit increase of specific 
dietary nutrients is shown in Table 10.  Dietary protein was found to be positively 
associated with serum IGF-1 concentration (p< 0.001). In the fully adjusted model 
including physical activity, each daily 1 g higher dietary protein intake was associated 
with a 0.030 nmol/L higher serum IGF-1 concentration (95% CI 0.027 to 0.033).  
When dietary protein was calculated relative to body mass (g/kg), every daily 1 g 
higher dietary protein intake per kg body mass was associated with a 1.043 nmol/L 
higher serum IGF-1 concentration (95% CI 0.908 to 1.178).   
When the relationship between physical activity and serum IGF-1 concentration was 
assessed in the fully adjusted model, a significant and positive association was found 
for moderate physical activity (10 to 50 excess MET h/week).  Individuals 
undertaking 10 to 50 excess MET h/week of physical activity had a serum IGF-1 
concentration that was 0.13 nmol/L greater than participants completing less than 10 
excess MET h/week of physical activity (95% CI 0.03 to 0.23).  However, the “high” 
category of physical activity (>50 excess MET h/week) was not correlated with serum 
IGF-1 concentration (-0.06 nmol/L; 95% CI -0.19 to 0.08). 
When dietary protein and physical activity were included in the same statistical 
model, physical activity did not change the relationship between dietary protein and 
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IGF-1 concentration, nor did dietary protein change the relationship between physical 
activity and IGF-1 concentration (Table 10).   
 
Table 10: Cross Sectional Multiple Linear Regression Results 
variable  coefficient 95% confidence interval 
Protein only model   
Protein(g) 0.020 (0.018, 0.022) 
Protein per body mass (g/kg) model   
Protein (g/kg) 1.043 (0.908, 1.178) 
Physical activity only model   
Physical Activity   
low 1 - 
moderate 0.220 (0.115, 0.325) 
high -0.026 (-0.162, 0.110) 
Protein and Physical activity only   
Protein(g) 0.020 (0.018, 0.022) 
Physical Activity   
low 1 - 
moderate 0.200 (0.094, 0.303) 
high -0.075 (-0.211, 0.060) 
Full Model ‡   
Protein(g)* 0.030 (0.027, 0.033) 
Physical Activity*   
low 1 - 
moderate 0.129 (0.028, 0.230) 
high -0.055 (-0.185, 0.076) 
Sex   
female 1 - 
male  1.133 (1.044, 1.222) 
Age at Recruitment -0.186 (-0.192, -0.181) 
Smoking Status   
never 1 - 
previous -0.179 (-0.269, -0.089) 
current -0.430 (-0.596, -0.263) 
BMI -0.103 (-0.114, -0.093) 
Alcohol Intake (g/day) -0.011 (-0.014, -0.008) 
Dietary Intake:   
energy (kJ) -0.035x10--2 (-0.041x10-2, -0.030x10-2) 
carbohydrate (g) 0.435x10-2 (0.290x10-2, 0.579x10-2) 
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fibre (g) 2.438x10-2 (1.552x10-2, 3.325x10-2) 
calcium (mg) 0.046x10-2 (0.027x10-2, 0.065x10-2) 
* note that the coefficient for protein is unchanged when physical activity is removed from the full 
model and vice versa. 
‡ full model is adjusted for: physical activity, sex, age at recruitment, smoking status, BMI, alcohol 
intake (g/day), energy intake (kJ/day), carbohydrate intake (g/day), fibre intake (g/day), and calcium 
intake (mg/day) 
 
Section 7.4 Discussion 
To date, this is the largest study assessing the association between dietary protein and 
IGF-1 concentration.  Our cross-sectional analysis revealed dietary protein was 
significantly associated with higher circulating IGF-1 concentration.  This is in 
agreement with previous cross-sectional research using smaller sample sizes, which 
resulted in magnitudes of effect ranging from 0.01 to 0.11 nmol/L of circulating IGF-1 
concentration for every 1 g/day of dietary protein (151, 152, 166).  Our results 
indicate that every 1 g higher daily dietary protein intake was associated with a 0.03 
nmol/L higher serum IGF-1 concentration.  If, for example, an individual were to add 
one standard serving (85 g) of chicken breast to their daily diet (an additional 26 g 
dietary protein), and assuming our results represent a causal association, this would 
increase their circulating IGF-1 concentration by 0.78 nmol/L.  Thus, it may be 
possible for an individual to significantly alter their circulating IGF-1 concentration 
with only minor adjustments to their daily diet.    
Interestingly, while moderate physical activity (10 to 50 excess MET h/week) was 
significantly associated with a higher circulating IGF-1 concentration, high levels of 
physical activity (over 50 excess MET h/week) were not significantly associated with 
circulating IGF-1 concentration.  The reasoning for which may be explained by recent 
research showing that type of exercise has a significant influence on the IGF-1 
response (259).  Resistance and sprint exercise have been shown to increase 
circulating IGF-1 concentration while endurance exercise to decrease circulating IGF-
1 concentration (259).  It is likely that those individuals accumulating the 50+ excess 
MET h of physical activity per week necessary to be included in the high activity 
category were performing multiple endurance-type exercise bouts rather than a high 
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volume of short sprint activities throughout the week. A previous publication utilising 
the accelerometer data from UK Biobank supports this theory and demonstrates that 
the majority of physical activity time is of light (40-100 milli-G (mg), which equates to 
<3 METs) or moderate (101-399 mg, which equates to 3-6 METs) intensity (260).  
This previous study analysed the accelerometer data from 26,192 healthy men and 
women and found that of the total time spent performing physical activity, healthy 
men spent a mean 162 min/day performing light activity, 96 min/day performing 
moderate activity, and 6.12 min/day performing vigorous activity (400 mg, which 
equates to 6 METs or greater) (260).  Healthy women spent a mean 182 min/day 
performing light, 104 min/day moderate and 4.8 min/day vigorous physical activity 
(260).  Thus, it is likely that the individuals accumulating the 50+ excess MET h of 
physical activity per week were performing predominantly endurance-type exercise, 
which is an exercise type that has not been shown to increase circulating IGF-1 
concentration in intervention studies (246).   While moderate physical activity was 
associated with higher circulating IGF-1 concentration, the regression coefficient 
represented by this relationship indicates that participants in the moderate physical 
activity category had an IGF-1 concentration 0.22 nmol/L greater than those in the 
low physical activity category.  Thus, while statistically significant, increasing physical 
activity from less than 10 excess MET h/week to between 10 and 50 excess MET 
h/week may not have a meaningful impact on circulating IGF-1 concentration.  For 
example, increasing physical activity from the low to moderate category is associated 
with the same increase in IGF-1 concentration as consuming an additional 7.3 g of 
protein/day (the equivalent of one extra-large egg).   
Notably, physical activity does not affect the relationship between dietary protein and 
IGF-1 concentration.  This is a novel finding of the study; our results indicate that 
alterations in dietary behaviour may be more effective than physical activity for 
altering resting IGF-1 concentration.  One plausible reason for the greater influence of 
dietary protein over physical activity may be due to the mechanism of release.  
Increasing dietary protein may cause an increase in circulating IGF-1 via a hepatic 
release of growth hormone, and subsequently IGF-1.  This mechanism of release has 
been shown to take longer than the acute release of IGF-1 from the muscle that is 
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released during exercise (261).  Therefore, the effects of exercise are likely to spike 
and dissipate quickly, while the influence of dietary protein may have a greater effect 
on chronic resting circulating IGF-1 concentration (261).  
7.4.1 Strengths and Limitations  
A major strength of this study is the large sample size.  We limited our analyses to 
participants who completed two or more 24 h dietary recall questionnaires, which 
slightly reduced our sample size but provided a more accurate measure of usual 
protein intake (262).  While not necessary in order to answer our research question, a 
limitation of this study is that we could not differentiate source of protein (animal, 
vegetable, milk protein, etc.).  In addition, the cross-sectional nature of this study 
means that we cannot be certain that our results represent causal associations.  
However, previous intervention studies in which energy was controlled showed 
elevated circulating IGF-1 concentration with increased protein intake (153, 156).   
Section 7.5 Conclusion 
The results of this cross-sectional analysis provide evidence of a positive association 
between dietary protein and circulating IGF-1 concentration.  This association is not 
influenced by physical activity. The strength of the association between dietary 
protein and circulating IGF-I concentration was stronger than that of physical activity 
and circulating IGF-I concentration.  Therefore, when seeking to adjust circulating IGF-
1 concentration for possible health concerns, regulating dietary protein may be more 






8. GENERAL DISCUSSION 
 
The research presented in this thesis systematically evaluated previously 
published literature on dietary protein and total IGF-1 concentration, and on exercise 
and total IGF-1 concentration.  The knowledge of the time course effects of protein 
and/or exercise on free IGF-1 concentration was enhanced.  In addition, this thesis 
produced the first study to describe the time course response of free IGF-1 
concentration to acute dietary protein ingestion (with and without prior exercise).  
The culminating study is the largest cross-sectional study to date assessing the 
association between chronic dietary protein, physical activity and total IGF-1 
concentration.   
8.1 Dietary Protein and IGF-1  
The results of the meta-analysis of dietary protein and total IGF-1 concentration 
indicates that there is a positive association between protein and total IGF-1 
concentration.  There was, however, a high level of heterogeneity associated with 
studies lasing longer than 10 days, and in the cross-sectional studies.  Thus, in order to 
provide a confident and precise estimate of the magnitude of the association between 
dietary protein and total IGF-1 concentration more well designed, and appropriately 
powered, randomised controlled trials are needed.  Ideally these studies would last 
longer than 10 days and take measurements of IGF-1 concentration both before and 
after the 10-day mark.    
The intervention study results indicated that free IGF-1 concentration was 
significantly greater in the fasted, rested state 24 h after the first basal measure, but at 
no other time point.  Thus, it is possible that the hepatic release of IGF-1 is a slow 
process and any rise in IGF-1 concentration caused by dietary protein may not be 
immediately observed in the circulation.  
The results of the analysis of UK Biobank data (0.030 nmol/L rise in IGF-1 per one g 
increase in protein intake) concurs with the results of the meta-analysis (0.033 
nmol/L rise in IGF-1 per one g increase in protein intake)  and provides further 
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evidence of a positive association between dietary protein and circulating total IGF-1.  
While not necessary in order to answer our research question, in the UK Biobanks 
study, we did not differentiate source of protein (e.g. animal, vegetable, dairy, soy 
protein,).  Future research utilising a large sample size and separating by source of 
protein may provide evidence as to whether or not type of protein differentially 
affects circulating total and free IGF-1.  In totality, the results of this thesis indicate a 
positive association between dietary protein and both total and free IGF-1 
concentration, both acutely and long term.  
8.2 Exercise and IGF-1  
The results of the meta-analysis of exercise and total IGF-1 concentration provides 
evidence indicating that the association between exercise and total IGF-1 
concentration is dependent upon the type of exercise.  Despite the studies in our 
meta-analyses being split into subgroups by type of exercise, the heterogeneity in 
many of these subgroups remained high (I2> 50%). We concluded that the source of 
heterogeneity is the inherent to the individual study designs. Therefore, in general, 
there is a need for appropriately powered, randomized controlled studies utilizing 
consistent exercise protocols (duration, mode, and type of exercise). In addition, our 
research focused on total IGF-1 concentration (as this was the most common measure 
reported) and does not take into account bioavailability, either by measuring free IGF-
1 or IGF-1 binding proteins. Future research investigating the effects of IGF-1 binding 
proteins and/or free IGF-1 concentration may provide more insight into how much 
IGF-1 is being produced and how much is biologically active. The high volume of 
studies (n = 117) that were unable to be included in this meta-analysis highlights the 
importance of reporting data in a manner, or making supplementary data files 
available, such that inclusion in meta-analyses is facilitated.  
The intervention study measured the concentration of free IGF-1 in response to a 
single bout (20 min with 4 sprints) of cycling exercise.  The free IGF-1 concentration 
increased immediately after exercise, which agrees with the results of the meta-
analysis studies, where total IGF-1 concentration increased immediately after sprint 
exercise.  The intervention study results expanded upon the results of the meta-
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analysis by measuring samples up to 24 h post-exercise, with no other time points 
being significantly different from baseline.  Thus, the effects of a repeated sprint 
exercise appear to produce an immediate but transient increase in free IGF-1 
concentration.  This suggests a possible localised release of free IGF-1 from the active 
muscle (195), as opposed to the delayed increase in IGF-1 concentration observed 
formerly by a dietary protein induced hepatic production of IGF-1 (198).   
While the results of the meta-analysis and intervention study assessed the immediate 
effects of exercise on total and free IGF-1 concentration, the UK Biobank study 
evaluated the association between habitual physical activity and resting total IGF-1 
concentration.  Therefore, since the intervention study suggested a short and 
transient increase in free IGF-1 due to repeated sprint exercise, with no significant 
increase from baseline the following morning, physical activity was not expected to be 
associated with increased total IGF-1 concentrations.  It was surprising, however, that 
the results of the cross-sectional study utilising UK Biobank participants showed that 
only moderate physical activity (10 to 50 excess MET h/week) was significantly 
associated with a higher total IGF-1 concentration, as opposed to high levels of 
physical activity (over 50 excess MET h/week).   The reasoning behind these results 
may be due, in part to the fact that the UK Biobank was not able to differentiate 
between resistance and sprint exercise types.  The meta-analysis results suggested 
that exercise type influences the total IGF-1 response, with endurance exercise not 
increasing total IGF-1 concentration.  The high activity category (50+ excess MET h of 
physical activity per week) equates to 16 h 40 min of exercise per week at a moderate 
intensity (3 MET) (263).  Thus, it is likely that individuals accumulating 16 h 40 min of 
physical activity per week were performing multiple endurance-type exercise bouts 
rather than a high volume of short sprint activities throughout the week.  The 
moderate activity category (10 to 50 excess MET h/week) equates to a duration of 
exercise per week between 3 h 20 min and 16 h 40 min at a moderate intensity (3 
MET) (263).  This disparity between categories could help to explain why the high 
activity category had a lower total IGF-1 concentration than the moderate activity 
category.  In addition, if individuals in the high activity category are, indeed, 
performing continuous endurance type activities, it is likely that they were in a 
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negative energy balance more often than the moderate activity category.  States of 
negative energy balance have been shown to decrease total IGF-1 concentration (264).  
Thus, if the individuals performing high amounts of physical activity are engaged in 
long endurance type activities, which subsequently put them at greater risk of being in 
negative energy balance, then this could be one of the contributing factors to highly 
active participants not having an elevated total IGF-1 concentration.  Lastly, cross-
sectional studies have a lower strength of evidence than meta-analyses or 
intervention studies.  Thus, more confidence can be placed in the results of the 
preceding studies as opposed to the unexpected cross-sectional results.   
Overall, the results of this thesis suggest that resistance and sprint exercise types 
acutely increase total and free IGF-1 concentration, while endurance-type exercise 
acutely decreases total IGF-1 concentration and that habitual physical activity in the 
range of 3 h 20 min to 16 h 40 min of moderate physically activity per week (3 MET) is 
associated with a higher total IGF-1 concentration.  
8.3 Combined Effect of Exercise and Dietary Protein on IGF-1  
Our intervention study results demonstrate that the timing and magnitude of plasma 
free IGF-1 concentration are influenced differently by exercise, than with protein 
ingestion, or when protein ingestion is preceded by exercise.  Free IGF-1 
concentration was increased immediately after exercise and dietary protein increased 
IGF-1 concentration 24 h after baseline.  Exercise with dietary protein, however, did 
not result in any significant changes in free IGF-1 concentration.  In our study, IGF-1 
binding proteins were not measured. Thus, when seeking to provide an explanation 
for the lack of effect on IGF-1 concentration the following morning when protein 
ingestion was preceded by exercise, we were unable to address the possibility that 
exercise induced increase in IGF-1 binding proteins (265) might reduce the quantity 
of free IGF-1 in circulation.   
Since our study was the first with a 24 h measure to investigate the effects of exercise 
with protein on free IGF-1, we were surprised by the lack of additive, or perhaps 
synergistic, effect when protein ingestion was preceded by exercise.  The total lack of 
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response at 24 h suggests a potential antagonism action exists from the interaction of 
protein ingestion and exercise.  We cannot explain why such an action would occur, 
but it could represent pre- or post-secretion regulatory events that control free IGF-1 
levels in the circulation and maintain homeostasis.  Future research needs to pursue 
this interesting finding and elucidate the mechanism(s).  
The cross-sectional analysis results indicate that the positive association between 
dietary protein and total IGF-1 concentration is not influenced by physical activity. 
Moreover, the strength of the association between dietary protein and circulating total 
IGF-I concentration was stronger than that of physical activity and circulating total 
IGF-I concentration.  Given the association between total IGF-1 concentration and 
incidence of certain types of cancer and mortality, future research should investigate 
if/how individuals with a high protein intake and/or high levels of physical activity 
are associated with higher incidence of cancer or mortality.  
Acutely, the combination of dietary protein with exercise does not alter free IGF-1 
concentration when compared to a fasted, resting baseline measure.   Chronically, 
physical activity does not moderate the relationship between dietary protein and total 
IGF-1 concentration.  
8.4 Conclusion 
Our results serve to guide individuals seeking increased total or free IGF-1 
concentration towards resistance exercise, while others may wish to preferentially 
select endurance exercise to lower total IGF-1 concentration.   However, the 
association between dietary protein and circulating total IGF-I concentration is 
stronger than that of physical activity and circulating total IGF-I concentration.  Thus, 
when seeking to adjust total IGF-1 concentration, regulating dietary protein may be 
more pertinent than physical activity as a primary intervention.  One such way in 
which to regulate the harmful effects of a diet high in dietary protein may be to 
perform exercise.  This is evidenced by our results, in which we found the 24 h 
increase in free IGF-1 produced by dietary protein alone was mitigated by performing 
exercise with protein.  Future research may provide insight into how modifying 
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dietary protein and/or physical activity, and thus free or total IGF-1 concentration, 
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Protein, Insulin-like Growth Factor (IGF-1) and Exercise: A Systematic Review 
  
Colleen Gulick1, Nancy Rehrer1, Meredith Peddie2, Anthony Hackney3 
  
1 School of Physical Education, Sport & Exercise Sciences, University of Otago 
2 Department of Human Nutrition, University of Otago 
1 Department of Exercise and Sport Science, University of North Carolina 
  
Background: Insulin-like growth factor-I is associated with multiple physiologic 
outcomes including: increased muscle growth and repair as well as increased cancer 
risk. Nutritional status (e.g. protein intake) has been observed to influence circulating 
IGF-1. However, effects of dietary protein intake on IGF-1 are inconsistent. 
Aim: To conduct a systematic review and meta-analysis to determine the relationship 
between IGF-1 and dietary protein intake. 
Methods: Searches of Scopus, PubMed, Sport Discus, Web of Science, and Academic 
Search Complete databases up to September, 2017 retrieved 6,271 publications, 
which were subsequently screened to determine if they met inclusion criteria. Papers 
were screened independently in duplicate and data are currently being extracted from 
relevant studies. 
Results: If the systematic review reveals groups of studies that are homogeneous then 
meta-analyses may be performed using STATA. We will evaluate statistical 
heterogeneity using the Chi-square (X2) statistic. Publication bias will be explored 
using funnel plots. 
Based upon the review of the literature we anticipate conducting subgroup analyses 
to investigate if aspects of study design such as: sampling timing (relative to feeding), 
source of protein (animal versus vegetable), and quantity of protein ingested affect 







Gulick C, Peddie M, Rehrer NJ. Exercise and Insulin-like Growth Factor (IGF-1): A 
Systematic Review and Meta-Analysis. Poster Presented at: Sport and Exercise Science 
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Exercise and Insulin-like Growth Factor (IGF-1): A Systematic Review & Meta-
Analysis 
  
1Gulick, C; 2Peddie, M; 1Rehrer, N 
  
1 School of Physical Education, Sport & Exercise Sciences, University of Otago 
2 Department of Human Nutrition, University of Otago 
 
  
Introduction: Insulin-like growth factor-1 concentration [IGF-1] is associated with 
multiple physiologic outcomes including increased muscle growth and repair and 
increased cancer risk. Exercise has been observed to influence circulating [IGF-1]. 
However, effects of exercise on [IGF-1] are inconsistent. 
Aim: To conduct a systematic review and meta-analysis to determine the relationship 
between [IGF-1] and exercise. 
Methods: Searches of Scopus, PubMed, Sport Discus, Web of Science, and Academic 
Search Complete databases up to September, 2017 retrieved 4,006 publications, 
which were subsequently screened. Eighty-five studies met the inclusion criteria and 
were included in the meta-analysis. Separate analyses were performed for studies that 
sampled total [IGF-1] before and after exercise without a control group (n=71) and 
studies that utilized a control group (n=14).   
Results: When compared to resting [IGF-1] before exercise, exercise interventions 
without a control group resulted in increases of [IGF-1] (Cohen’s d=0.276, 95% CI 
0.181 to 0.371, I2=73.2%).  Subgroup analysis revealed type of exercise (p<0.001) was 
a source of heterogeneity, with exercise performed with blood flow restriction, 
endurance exercise, and ultra-endurance racing reducing [IGF-1], while resistance, 
sprint, and resistance with sprint exercise increasing [IGF-1]. 
When exercise was compared to a non-exercise control exercise was found to induce a 
small increase in [IGF-1] (Cohen’s d=0.351, 95% CI 0.043 to 0.659, I2=83.9%).  Again, 
exercise type was found to be a source of heterogeneity with endurance and sprint 
exercise producing small reductions in [IGF-1], while resistance exercise and blood 
flow restriction produced a small to large increase in [IGF-1].      
Conclusions: This is the first meta-analysis investigating the effects of exercise on 
[IGF-1].  The nature of the response is largely determined by type of exercise.  
Resistance exercise increases [IGF-1] while endurance exercise decreases [IGF-1].  
Therefore, based upon the acute [IGF-1] response, it is speculated that endurance 
exercise may be more beneficial for those with increased risk of cancer and resistance 
exercise for those wanting to maximize muscle gain.     
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Introduction: Insulin-like growth factor-1 (IGF-1) is an anabolic hormone that 
stimulates cell growth and cell division.  While beneficial for growth/repair, and 
regulating muscle hypertrophy, high IGF-1 concentration [IGF-1] is associated with 
increased risk of some cancers and mortality.  Factors thought to mediate [IGF-1] 
include dietary protein and exercise.  The purpose of this study was to analyse acute 
effects of dietary protein and/or exercise on plasma free [IGF-1] and the time-course 
of changes, in order to inform individuals who may benefit from increased [IGF-1] 
(muscle growth/repair) or reduced [IGF-1] (risk/diagnosis of cancer).   
Methods: Twenty-four participants (11 females/13 males, 24.9 ± 4.6 y) completed the 
three-way crossover study consisting of: (1) a high protein (45 g; 1707 kJ) meal; (2) 
exercise (20 min including four 30 s sprints); and (3) exercise followed by a high 
protein meal.  Blood samples were collected fasted at rest, immediately after rest (or 5 
min after exercise), and at regular intervals throughout the following 5 h.  An 
additional fasted blood sample was taken the morning following each condition (24 h 
after baseline).  A linear mixed-effects regression was run to investigate the change in 
[IGF-1] over time for all three conditions with tests of simple main effects to 
determine which time points were significantly different from baseline in each 
condition.   
Results: [IGF-1] was higher at 30 min (immediately after exercise) in the exercise 
condition (p= 0.04).  In the protein condition the 24 h [IGF-1] was 17.5% higher (p= 
0.02) than baseline.  [IGF-1] did not change over time in response to exercise with 
protein. Area under the [IGF-1] curve was calculated by trapezoidal reconstruction for 
the time period between baseline and 300 min and was not significantly different 
between conditions.   
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Conclusion: This research has implications for those seeking to increase or decrease 
[IGF-1], with repeated protein meals likely being necessary to increase basal levels of 
[IGF-1] in non-exercising individuals, and reduced protein intake with increased 
exercise to keep [IGF-1] low for individuals seeking protection against potential 
harmful effects of long term increases in [IGF-1].   
 
 
APPENDIX B: Exercise and IGF-1 Characteristics and Results for Studies without a Control Arm 
 
 
Table 4: Characteristics and Results for Studies without a Control Arm 
 






























Single leg extension: 4 sets of 
75% 1 RM until failure 









Single leg extension: 4 sets of 
75% 1 RM until failure 
ng/mL 10 160.5 68.9 Immediately 153.1 70.6  
Berg et al. 
(2012) 
1 Sprint 1 h ng/mL 15 220 77 
1 h after 
exercise 
265 66.7  





Adventure Racing World 
Champ (800 km) 
ng/mL 7 326 73.5 Immediately 151 43.25 Females 





Adventure Racing World 
Champ (800 km) 
ng/mL 9 250 34.75 Immediately 138 28.25 Males 
Berg et al. 
(2007) 
1 Resistance 1 h ng/mL 7 230 42 
10 min post 
exercise 
224 60 Females 
Berg et al. 
(2007) 
1 Resistance 1 h ng/mL 7 202 38 
10 min post 
exercise 




4 sets of bench, leg press, 
seated bar shoulder press, arm 
curls, lat pull down at 80% 1 
RM. 2 min rest between sets. 
Each set to exhaustion. 
ng/mL 9 103.77 19.1 Immediately 141.68 13.45 Males 
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Velocity: 3 s eccentric, 1 s 
concentric. 
Bosco et al. 
(1996) 
1 Sprint 
60 s consecutive vertical 
jumps (Bosco Test) 
ng/mL 16 106.4 42.5 Immediately 117.5 59.4 Males 
Brahm et al. 
(1997) 
1 Resistance 
Single leg extensions: 10 min 
warm up, 15 min at 61% peak 
one leg VO2max, 5 min work at 
peak one leg VO2max (25 min 
total) 
ng/mL 12 181 21 Immediately 198 25  
Brahm et al. 
(1997) 
1 Resistance 
Single leg extensions: 10 min 
warm up, 15 min at 61% peak 
one leg VO2max, 5 min work at 
peak one leg VO2max (25 min 
total) 
ng/mL 12 170 16 Immediately 215 24  
Consitt et al. 
(2008) 
1 Sprint 
Cycling: 30 min at 70% 
VO2max 




Cycling: constant load for 90 
min 
ng/mL 7 441 151 Immediately 396 115  
DePalo et al. 
(2008) 
1 Sprint 
Cycling: 10 min warm up, 15 
min at exhaustion 
nmol/L 20 66 10 Immediately 70 10 Males 
DePalo et al. 
(2008) 
1 Sprint 
Cycling: 10 min warm up, 15 
min 70-80% VO2max, 15 min 
increasing workload until 
exhaustion 
nmol/L 20 55 14 Immediately 61 15 Males 
DePalo et al. 
(2004) 
1 Endurance Cycling: 102 km race (~2.5 h) ng/mL 20 262.6 13.4 Immediately 247.3 11.8 Males 
DePalo et al. 
(2003) 




Sport specific maximal 
exercise test 




Sport specific maximal 
exercise test 
ng/mL 33 325 106 Immediately 348 121 Females 
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Fragala et al. 
(2014) 
1 Resistance 
Resistance + cold water 
immersion. 4 sets of up to 10 
reps barbell back squat at 80% 
1 RM, barbell dead lift & split 
squat at 70% 1 RM, 90 s rest 
between each set & exercise. 
Immediately after exercise 
cold water immersion for 10 
min at 10-12 deg C 
ng/mL 10 72.02 14.8 








in cold water or 
not for the 
post-exercise 
blood sample 
Fragala et al. 
(2014) 
1 Resistance 
4 sets of up to 10 reps barbell 
back squat at 80% 1 RM, 
barbell dead lift & split squat 
at 70% 1 RM, 90 s rest 
between each set & exercise. 
ng/mL 10 72.02 14.8 




taken on day 1. 




Badillo et al. 
(2016) 
1 Resistance 
3 sets of 4 reps bench press & 
squat, 10 min rest between 
exercises 
ng/mL 9 284.7 73.5 
5 min after 
exercise 
301.8 78.2 Males 
Gonzalez-
Badillo et al. 
(2016) 
1 Resistance 
3 sets of 8 reps (until failure) 
bench press & squat, 10 min 
rest between exercises 
ng/mL 9 299.4 73.6 
5 min after 
exercise 
352.6 94.8 Males 
Headley et al. 
(2011) 
1 Resistance 
1 RM bench press test with 
2/0/2 tempo 
ng/mL 12 277.4 21.8 Immediately 308.1 22.9 
Mean 1 RM 
247.5 +/- 12.9 
lbs. Total work 
performed 
including warm 
up sets was 
5987.8 ± 297.9 
J 
Headley et al. 
(2011) 
1 Resistance 
1 RM bench press test with 
2/0/4 tempo 
ng/mL 12 277.2 17.6 Immediately 284.8 21.2 
Mean 1RM 
237.9 +/- 12.5 
lbs. Total work 
completed 
including warm 
up sets 5339.5 
± 259.7 J. 
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Hopkins et al. 
(1994) 
1 Endurance 
Cycle to fatigue at 60% of VO2 
max 
ng/mL 4 682 85 Immediately 722 79 Males 
Hornum et al. 
(1997) 
1 Sprint 
Cycling: 10 min with intensity 
midway between LAT and 
VO2peak 




not involved in 
sport or 
training 
Hornum et al. 
(1997) 
1 Sprint 
Cycling: 10 min with intensity 
midway between LAT and 
VO2peak 








Jahreis et al. 
(1989) 
1 Endurance Marathon U/mL 9 1.15 0.34 Immediately 1.21 0.33 Males 






Recumbent cross trainer: 5 
min warm up <100 W, 10 min 
100-150 W, 5 x 20 s sprints 
with 40 s relaxed <100 W with 
30 min passive recovery. Cuffs 
on arms & legs pressure 
between 60-80 mmHg. 
ng/mL 18 197.4 32 
2 min after 
exercise 
190.4 17.7 




Jurimae et al. 
(2005) 
1 Sprint 
Rowing ergometer: 30 min 
max test 
ng/mL 13 232.6 100 Immediately 251.1 59 Males 
Jurimae et al. 
(2007) 
1 Sprint 
Rowing ergometer: 6000m test 
(mean time 19 min 52 s ± 16.4 
s) 
ng/mL 8 237.7 83.9 Immediately 268.3 91.7 





Kaspar et al. 
(2016) 
2 Sprint 
Cycling: 62.5% of max HR for 
45 min 
pg/mL 7 345.3 70 
30 min after 
exercise 
302.4 47  
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Kaspar et al. 
(2016) 
2 Sprint 
Cycling: 2 min warm up at <50 
W, 6 sets of 30 s all out on self-
selected gearing. 4 min rest 
between sets at <30 W 
pg/mL 7 345.3 70 
30 min after 
exercise 
299 34  
Kochańska-
Dziurowicz 
et al. (2015) 
1 Sprint 
Cycling: 21 min work (mean 
3261.3 J/kg) 
ng/mL 20 268.9 59.8 Immediately 287.4 58.8 
Male ice hockey 
players 
Kon et al. 
(2009) 
2 Resistance 
2 sets of 10 reps at 70% of 1 
RM: bench press, bilateral leg 
press. Rest 1 min between all 
sets & exercises. 
ng/mL 12 273.4 30.9 Immediately 303 33.4 Normoxia 
Kon et al. 
(2009) 
2 Resistance 
2 sets of 10 reps at 70% of 1 
RM: bench press, bilateral leg 
press. Rest 1 min between all 
sets & exercises. 
ng/mL 12 247.7 16.7 Immediately 274.2 33.4 
Hypoxia (13% 
oxygen) 
Li et al. 
(2015) 
2 Resistance 
4 sets of 10 reps at 80% 1 RM 
leg press & leg extension 
ng/mL 10 257.61 69.9 
30 min after 
exercise 
275.62 88.85 Males 
Maddalozzo 
et al. (2000) 
2 Resistance 
Seated machine based 
programme of moderate 
intensity (75 min) 
ng/mL 13 168.38 57.5 Immediately 170.23 67.7 Older males 
Maddalozzo 
et al. (2000) 
2 Resistance 
Seated machine based 
programme of moderate 
intensity (75 min) 
ng/mL 13 148.62 44.9 Immediately 148.22 53.5 Older females 
Maddalozzo 
et al. (2000) 
2 Resistance 
Standing free-weight based 
programme of high intensity 
(75 min) 
ng/mL 15 171.87 53.07 Immediately 168 45.8 Older males 
Maddalozzo 
et al. (2000) 
2 Resistance 
Standing free-weight based 
programme of high intensity 
(75 min) 
ng/mL 12 166.33 36.6 Immediately 167.75 40.9 Older females 
Maimoun et 
al. (2004) 










Low load (20% 1 RM) ng/mL 10 269 22.6 Immediately 255.4 26.9 Males 
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Manini et al. 
(2012) 
1 Resistance 
High load without blood flow 
restriction (80% 1 RM) 
ng/mL 10 273.2 34.8 Immediately 255.4 26.9 Males 
Mannerkorpi 
et al. (2017) 
1 Sprint 
Cycling: 15 min at low 
intensity (12-13 RPE) 
ng/mL 27 179 69 Immediately 192 10 Females 
Mannerkorpi 
et al. (2017) 
1 Sprint 
Cycling: 15 min at high 
intensity (15-17 RPE) 
ng/mL 27 181 66 Immediately 200 22 Females 
Majri et al. 
(2005) 
1 Sprint Football: normal training ng/mL 13 414 114 




players at the 
beginning of 
the season 
McCall et al. 
(1999) 
1 Resistance 
3 sets at 10 RM of 8 exercises 
with 1 min rest between sets & 
exercises. 





Mitchell et al. 
(2013) 
1 Resistance 
Progressive programme with 2 
upper body exercises & 2 
lower body exercises 
nM 23 38 14 Immediately 39 26 Males 
Mkacher et 
al. (2014) 
1 Resistance Not reported ng/mL 16 143.67 8.86 Immediately 147.78 9.87 Males 
Moro et al. 
(2016) 
2 Resistance 
3 sets of 6-8 reps at 85-90% 1 
RM to failure. Split routine: 
upper body, back & legs, back. 
180 s rest between sets & 
exercises. 
ng/mL 17 215.59 56.25 Immediately 218.41 42.24 Males 
Morton et al. 
(1985) 
2 Resistance 
3 sets of incline leg press, 
hamstring curl & knee 
extension superset with 1 min 
rest between supersets 







Nemet et al. 
(2009) 
1 Sprint 
Run: 4 x 250 m at 80% max 
speed 
ng/mL 12 350.2 45.9 Immediately 383 40 Males 
Nichols et al. 
(1994) 




Nindl et al. 
(2012) 
1 Resistance 
10 sets of 10 plyo jump reps at 
40% 1 RM 
ng/mL 8 602.17 65.55 Immediately 650.85 70.1 
Male army 
members 
Nindl et al. 
(2012) 
1 Resistance 
10 sets of 10 plyo jump reps at 
40% 1 RM 
ng/mL 12 490.79 53.52 Immediately 544.64 57.24 
Female army 
members 
Paoli et al. 
(2015) 
3 Resistance 
2 sets of 9-11 reps at 75-80% 
upper body exercise. 2 min 
breaks between sets & 
exercises. Increase number of 
sets with the weeks. 
ng/mL 9 229.4 20.84 Immediately 223.6 22.3 
Normal protein 
group on day 1, 
active 5-6 
h/week 
Popov et al. 
(2005) 
1 Resistance 
7 sets of 6-12 reps at 80% MVC 
leg press. 10 min pauses for 
recovery. 
ng/mL 9 277 39 Immediately 259 29 Week 2 
Popov et al. 
(2005) 
1 Resistance 
4 sets of 3 bouts of 50-60 s to 
exhaustion with 30 s rest at 
50% MVC leg press & no 
relaxation. 10 min pauses 
between sets. 
ng/mL 9 320 50 Immediately 350 47 Week 2 
Rahimi et al. 
(2018) 
1 Sprint Treadmill: Bruce test ng/mL 10 176.9 30.1 Immediately 210.3 26.7 
Non-athlete 
females 
Rahimi et al. 
(2018) 
1 Sprint Treadmill: Bruce test ng/mL 10 187.7 29.3 Immediately 249.8 24.3 Athlete females 







Sprint running, resistance 
training, sprint cycling: 13 
sessions of each, no longer 
than 70 min each 











Sprint running, resistance 
training, sprint cycling: 13 
sessions of each, no longer 
than 70 min each 












Sprint running, resistance 
training, sprint cycling: 13 
sessions of each, no longer 
than 70 min each 











Sprint running, resistance 
training, sprint cycling: 13 
sessions of each, no longer 
than 70 min each 




Stokes et al. 
(2005) 
2 Sprint 
Cycle ergometer: 30 s 
separated by 60 min. 
Resistance 7.5% body mass 
ng/mL 8 235.6 42.3 Immediately 273.8 64.5 
Males after 
sprint 1 
Stokes et al. 
(2005) 
2 Sprint 
Cycle ergometer: 30 s 
separated by 240 min. 
Resistance 7.5% body mass 
ng/mL 8 251.6 69.7 Immediately 281.4 96.5 
Males after 
sprint 1 
Stokes et al. 
(2005) 
2 Sprint 
Cycle ergometer: Single 30 s 
sprint carried out the day after 
the trial with 240 min 
recovery. Resistance 7.5% 
body mass 
ng/mL 8 248.8 69 Immediately 276.2 74.8 
Males after 
sprint 2 
Suikkari et al. 
(1989) 
2 Endurance 
Cycling: 3 h at 45-50% max 
aerobic power 
ng/mL 11 203 48 Immediately 194 32 
Males in study 
part 1 
Suikkari et al. 
(1989) 
2 Endurance 
Cross country ski race: 7.5 h 
(75 km) 
ng/mL 10 90 18 Immediately 73 11 
Non-diabetics 
from study part 
2 






30 reps after 20 s rest at 20% 
1 RM, 3 sets until exhaustion of 
bilateral leg extension.  Band 
pressure 1.3x resting systolic 
BP (160-180 mmHg). 
ng/mL 11 210 40 Immediately 236 56 Males 
Takano et al. 
(2005) 
1 Resistance 
30 reps after 20 s rest at 20% 
1 RM, 3 sets until exhaustion of 
bilateral leg extension without 
blood flow restriction 






5 sets of 6 maximal eccentric 
contractions of elbow flexors. 
2 min rest between each set 
ng/mL 8 225.9 14 Immediately 238.7 17.8 Males 
Wallace et al. 
(1999) 
1 Sprint 
Cycling ergometer: 5 min at 1 
W/kg, 5 min at 2 W/kg, 20 min 
at 65% workload achieved at 
VO2max (30 min total) 
nmol/L 17 25.2 0.2 Immediately 30.3 0.2 
Male placebo 
group only 
Wilk et al. 
(2018) 
1 Resistance 
3 sets of 3 reps of barbell 
squats at 90% 1 RM 




the national & 
international 
level 
Wilk et al. 
(2018) 
1 Resistance 
6 sets of 3 reps of barbell 
squats at 90% 1 RM 




the national & 
international 
level 
Wilk et al. 
(2018) 
1 Resistance 
12 sets of 3 reps of barbell 
squats at 90% 1 RM 




the national & 
international 
level 
Zaldivar et al. 
(2006) 
1 Sprint 
Cycling ergometer: 30 min 
above anaerobic or LT 




Arm ergometer: eccentric & 
concentric exercises 








*Exercise type: Sprint exercise includes exercise lasting 1 h or less and not resistance nor blood flow restriction exercise.  Endurance exercise includes exercise 















APPENDIX C: Exercise and IGF-1 Characteristics and Results for Studies with a Control Arm 
Table 5: Characteristics and Results for Studies with a Control Arm 































3 upper body exercises with 3 sets of 8 reps 
at 80% 1 RM. Lower body exercises with 3 
sets of 8 reps 80% 1 RM 
Immedia
tely 







3 upper body exercises with 3 sets of 8 reps 
at 80% 1 RM.  Lower body exercises with 1 
set of 30 reps followed by 2 sets of 15 reps at 
20% 1 RM. Cuff pressures individually & 
progressively increased from 45 mmHg up to 
70 mmHg for initial pressure and from ~160 
mmHg to 240 mmHg for the highest pressure 
used during training. Cuff maintained during 
30 s rest period between sets. Cuff deflated 
for 5-10 min between separate leg exercises. 
Total cuff inflation time ranged 6-8 min 
Immedia
tely 




Multiset exercises alternating between 10 to 
5 RM with 90 s rest between sets for 2 h 
1 h after 
exercise 
10 264 27 10 267 21 
Olesen et 
al. (2007) 
1 Endurance Run: 36 km at 12 km/h pace (3 h total) 
Immedia
tely 
6 242.5 14.5 6 160.2 11.7 
Scofield et 
al. (2011) 
1 Endurance Cycling: 60% VO2max for 60 min 
Immedia
tely 














Cycle ergometer: 30 s sprint with resistance 
equal to 7% of body mass 
Immedia
tely 




Cycle ergometer: 30 s sprint with resistance 
equal to 9% of body mass 
Immedia
tely 
4 196 43 7 192 24 
Tsai et al. 
(2014) 
2 Resistance 50% 1 RM for 40 min 
Immedia
tely 
10 226.1 42.3 20 262.1 52.8 
Tsai et al. 
(2014) 
2 Resistance 80% 1 RM for 40 min 
Immedia
tely 












4 sets of post training 12 RM of 3 thigh 




3 280 21 9 330 22 
Wahl et al. 
(2013) 
2 Endurance 




7 420 191 7 478 113 
Wahl et al. 
(2013) 
2 Endurance 




7 457 113 7 497 127 
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APPENDIX D: Exercise and IGF-1: Characteristics and Results for Studies not able to be Included in the Meta-Analyses 
 
 































W or 28 ± 2 W 
depending on 








ug/L 18 Immediately Increase Pre/Post p> 0.05 





flow, & high 
intensity non-
restricted blood 
flow.  None of the 
arms were 
significantly 
different from each 
other so the IGF-1 
concentrations are 
averaged together 
for all conditions 
Berg et al. 
(1997) 
1 Endurance 




VO2max at 60 
rpm 
ug/L 9 Immediately Increase Pre/Post p> 0.05  













sets of 8-10 
reps at 80% 1 











curls, lat pull 
down at 65% 
1 RM. 2 min 
rest between 
sets. Each set 
to exhaustion. 
Velocity: 3 s 
eccentric, 1 s 
concentric. 
ng/mL 9 Immediately Increase Pre/Post p> 0.05 Males 







ng/mL 11 Immediately Increase Pre/Post p< 0.05  
Copeland et al. 
(2002) 
1 Resistance 
3 sets of 10 
reps of 8 
exercises 
ug/L 6 Immediately Increase Pre/Post p> 0.05 Ages 19-31 
Copeland et al. 
(2002) 
1 Resistance 
3 sets of 10 
reps of 8 
exercises 
ug/L 6 Immediately Increase Pre/Post p> 0.06 Ages 31-37 
Copeland et al. 
(2002) 
1 Resistance 
3 sets of 10 
reps of 8 
exercises 
ug/L 6 Immediately Decrease Pre/Post p> 0.07 Ages 40-49 
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Copeland et al. 
(2002) 
1 Resistance 
3 sets of 10 
reps of 8 
exercises 
ug/L 6 Immediately Increase Pre/Post p> 0.08 Ages 50-55 




min at 75% 
max HR 
ug/L 6 Immediately Increase Pre/Post p> 0.09 Ages 19-31 




min at 75% 
max HR 
ug/L 6 Immediately Increase Pre/Post p> 0.10 Ages 31-37 




min at 75% 
max HR 
ug/L 6 Immediately Decrease Pre/Post p> 0.11 Ages 40-49 




min at 75% 
max HR 
ug/L 6 Immediately Increase Pre/Post p> 0.12 Ages 50-55 





2.5% slope, 4 
min warmup 






for 30 min 
 7 Immediately Decrease Pre/Post p> 0.13  








nmol/L 6 Immediately Increase Pre/Post p< 0.05  






20 min after 
exercise 
Increase Pre/Post p< 0.05 Males 






20 min after 
exercise 
Increase Pre/Post p> 0.05 Females 
Far et al. 
(2011) 
1 Resistance 
















Far et al. 
(2011) 
1 Resistance 
4 exercises, 4 
sets at 70-













Forbes et al. 
(2014) 
1 Resistance 
3 sets of 8 
exercises, 10 
reps at 75% 1 
RM 
ng/L 14 Immediately Increase Pre/Post p> 0.05 Placebo group 
Goto et al. 
(2009) 
1 Endurance 








ug/L 10 Immediately Increase Pre/Post p< 0.01  




starting at 30 
W then 
increasing by 





ug/L 8 Immediately Decrease Pre/Post p> 0.05 
Used values before 
training 
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Ho et al. (2002) 1 Resistance 
3 sets of 7 RM 
with 30 s rest 
between 
exercises & 




bench press, 2 
leg curl, arm 






15 min after 
exercise 
Increase Pre/Post p> 0.05 Control group 






5 min after 
exercise 
Not reported Pre/Post 
Not 
reported 
Young lean group 






5 min after 
exercise 





Izquierdo et al. 
(2009) 
1 Resistance 






Not reported 12 Immediately Not reported Pre/Post p> 0.05  
Izquierdo et al. 
(2009) 
1 Resistance 






Not reported 12 Immediately Not reported Pre/Post p> 0.05  
















run: at 60% 
VO2max for 
10 min, 75% 
for 10 min, 
90% for 5 
min, 100% for 
2 min 




exercise & higher 
than non-exercising 
control. 
Kraemer et al. 
(1992) 
1 Resistance 
3 sets of 
bench press, 
lat pull, leg 
extension, leg 
curl at 10 RM 
load for 10 
reps or until 
failure 
ng/mL 8 
5 min after 
exercise 
Decrease Pre/Post p> 0.05  








sets of 10 
reps with 1 
min rest 
between set & 
exercise 
nmol/L 7 Immediately Increase Pre/Post p> 0.05  
Kraemer et al. 
(1991) 
1 Resistance 
8 exercises. 5 




nmol/L 8 Immediately Increase Pre/Post p< 0.05 P1 males 








nmol/L 8 Immediately Increase Pre/Post p< 0.05 P2 males 
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Kraemer et al. 
(1991) 
1 Resistance 
8 exercises. 5 




nmol/L 8 Immediately Increase Pre/Post p> 0.05 P1 females  








nmol/L 8 Immediately Increase Pre/Post p< 0.05 P2 females 
Kraemer et al. 
(2000) 
1 Sprint 
Cycling: 90 s 
maximal 
effort 
nmol/L 10 Immediately Increase Pre/Post p> 0.05  
Kraemer et al. 
(2007) 
1 Resistance 
1 set max 
effort 10 CMJ, 
max isometric 
squat, 6 sets 
of squats to 
failure at 80% 
1 RM, 1 set 10 
CMJ, 2 min 
rest between 
each set & 
exercise 















on day 1 






RM x 5 sets. 3 
min rest 
nmol/L 9 Immediately Increase Pre/Post p> 0.05  






10 RM x 3 
sets. 1 min 
rest 
nmol/L 9 Immediately Increase Pre/Post p> 0.05  
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RM x 5 sets. 1 
min rest 
nmol/L 9 Immediately Increase Pre/Post p> 0.05  







RM x 5 sets. 3 
min rest 
nmol/L 9 Immediately Increase Pre/Post p> 0.05  







RM x 3 sets. 3 
min rest 
nmol/L 9 Immediately Decrease Pre/Post p> 0.05  







RM x 3 sets. 1 
min rest 
nmol/L 9 Immediately Decrease Pre/Post p> 0.05  






RM x 5 sets. 3 
min rest 
nmol/L 9 Immediately Increase Pre/Post p< 0.05  






10 RM x 3 
sets. 1 min 
rest 
nmol/L 9 Immediately Increase Pre/Post p> 0.05  









RM x 5 sets. 1 
min rest 







RM x 5 sets. 3 
min rest 
nmol/L 9 Immediately Decrease Pre/Post p> 0.05  







RM x 3 sets. 3 
min rest 
nmol/L 9 Immediately Decrease Pre/Post p> 0.05  







RM x 3 sets. 1 
min rest 
nmol/L 9 Immediately Decrease Pre/Post p> 0.05  
Kraemer et al. 
(1998) 
1 Resistance 
4 sets x 4 
exercises, 





at 10 RM 
nmol/L 9 
15 min after 
exercise 
Increase Pre/Post p> 0.05 
Placebo condition 
on day 1 
Kraemer et al. 
(2003) 
1 Resistance 
Squats 5 sets 
of 15-20 reps  
nmol/L 10 Immediately Increase Pre/Post p> 0.05 Placebo condition 





 7 Immediately Increase Pre/Post p> 0.05 Placebo condition 






















































































at 80% max 
speed of 100 
m 










at 80% max 
speed of 100 
m 











6 min arm up 






60 rpm. 4 h 
rest between 
tests 




32.8 ± 4.3 ug/L 
after exercise 
Micielska et al. 
(2019) 
1 Sprint 






Not reported 20 
1 h after 
exercise 
Increase Control p< 0.05 
High-intensity 
circuit training 
group. Not reported 
whether 
significantly greater 
when compared to 
baseline or control 
group. 
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75-80% 1 RM 
for 3 sets with 





ng/mL 8 Immediately Increased Pre/Post p> 0.05 
Early follicular 
phase (days 4-7) 




75-80% 1 RM 
for 3 sets with 





ng/mL 8 Immediately Decreased Pre/Post p> 0.05 
Midluteal phase 
(days 7-10) 
Nassar et al. 
(2007) 
1 Resistance 
Leg press 7 
sets of 7 reps 
at 85% 1 RM 
ng/mL 30 
15 min after 
exercise 
Increased Pre/Post p> 0.05 
Males, placebo 
group 
Nassar et al. 
(2007) 
1 Resistance 
Leg press 7 
sets of 7 reps 
at 85% 1 RM 
ng/mL 30 
15 min after 
exercise 
Decreased Pre/Post p> 0.05 
Females, placebo 
group 





30 W every 3 
min until VT 




ng/mL 14 Immediately Increased Pre/Post p< 0.001  




race: 60 km 
(3 h) 
ng/mL 14 Immediately Decreased Pre/Post p< 0.001  






2 x 45 min 
ng/mL 11 Immediately Decreased Pre/Post p> 0.05  
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min at 60% 
peak aerobic 
power 
ng/mL 7 Immediately Decreased Pre/Post p> 0.05 
Overweight middle-
aged 




min at 80% 
peak aerobic 
power 
ng/mL 7 Immediately Increased Pre/Post p> 0.05 
Overweight middle-
aged 




70% MHR for 
25 min 
ng/mL 10 Immediately Decreased Pre/Post p> 0.05  





70% MHR for 
25 min 
ng/mL 10 Immediately Decreased Pre/Post p> 0.05  





MHR for 25 
min 
ng/mL 10 Immediately No change Pre/Post N/A  




85% MHR for 
25 min 
ng/mL 10 Immediately Increased Pre/Post p> 0.05  





85% MHR for 
25 min 
ng/mL 10 Immediately Increased Pre/Post p> 0.05  
Peeri et al. 
(2014) 
2 Sprint 
85% MHR for 
25 min 
ng/mL 10 Immediately Increased Pre/Post p> 0.05  



















ng/mL 10 Immediately Increased Control p> 0.05 
IGF-1 concentrating 
increased by 3% 
due to exercise. 
Control group 
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lat pull down. 
30 min. 4 sets 
10 reps at 
80% 10 RM. 
90 s rest 
decreased IGF-1 
concentration. 





at 70% max 
HR & 60-70 
rpm 
ng/mL 10 Immediately Increased Control p= 0.004 
IGF-1 concentration 
increased by 28.7% 



















ng/mL 10 Immediately Increased Control p= 0.037 
IGF-1 concentration 
increased by 25% 











at 160 deg, 




reps at 40% 
of max. repeat 
3 max 
contractions 
ng/mL 8 Immediately Increased Pre/Post p< 0.05  







ng/mL 8 Immediately Increased Pre/Post p< 0.01  
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at 160 deg, 




reps at 110% 
of max. repeat 
3 max 
contractions 




min warm up 
at 50% 
VO2max then 
65 min at 
75% VO2max 





& found no 
difference 




bouts of 10 
min warm up 
at 50% 
VO2max then 
65 min at 
75% VO2max. 









& found no 
difference 





sets of 10 
reps per leg 












with 50% of 
lean body 
mass 





sets of 10 
reps per leg 







with 50% of 
lean body 
mass 
mmol*min/L 10 Immediately Increased Pre/Post p< 0.01 Lean group 
Rubin et al. 
(2005) 
1 Resistance 
2-3 sets light 
squats warm 
up, 6 sets of 
parallel 
squats at 10 
RM, 2 min 
rest between 
sets. Goal of 
10 reps per 




mmol/L 10 Immediately Increased Pre/Post p< 0.05 Untrained 
Rubin et al. 
(2005) 
1 Resistance 
2-3 sets light 
squats warm 
up, 6 sets of 
parallel 
squats at 10 
RM, 2 min 
mmol/L 9 Immediately Increased Pre/Post p< 0.05 Trained 
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rest between 
sets. Goal of 
10 reps per 








min at 80% of 
LT 
ng/mL 10 Immediately Increased Control p< 0.04 
IGF-1 concentration 
increased by 7.7 ± 














ng/mL 10 Immediately Increased Control p< 0.002 
IGF-1 concentration 
increased by 13.3 ± 






Sharafi et al. 
(2012) 
1 Resistance 
4 sets 6 
exercises at 
80% 1 RM 
until failure 
ng/mL 9 Immediately Increased Pre/Post p< 0.05 Resistance trained 
Sharafi et al. 
(2012) 
1 Resistance 
4 sets 6 
exercises at 
80% 1 RM 
until failure 
ng/mL 9 Immediately No change Pre/Post p> 0.05 Untrained 
Sheikholeslami-








for 40 min 
ng/mL 11 Immediately Increase Pre/Post p> 0.05 
Placebo group on 
the 8th day 
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ng/mL 16 Immediately Increased Control p< 0.001 
Control group had a 
non-significant 
increase in IGF-1 
concentration.  
Spiering et al. 
(2008) 
2 Resistance 
5 sets 5 max 
reps of knee 
extensions 
nmol/L 7 Immediately Increased Pre/Post p> 0.05  
Spiering et al. 
(2008) 
2 Resistance 
5 sets 5 max 














nmol/L 7 Immediately Increased Pre/Post p> 0.05  
Taipale et al. 
(2019) 
2 Resistance 
10 sets 10 





sets 10 reps 
at 30% 1 RM) 
nmol/L 7 Immediately Increase Pre/Post p> 0.05 
Blood taken 
immediately after 
the active recovery 
Taipale et al. 
(2019) 
2 Resistance 
10 sets 10 





nmol/L 11 Immediately Increase Pre/Post p> 0.05 
Blood taken 
immediately after 




(sitting in a 
chair) 




press and leg 
extension 4 
sets of 18-20 
reps at 60-
65% 1 RM 
ng/mL 12 Immediately Increased Pre/Post p> 0.05  




press and leg 
extension 4 
sets of 8-10 
reps at 80-
85% 1 RM 
ng/mL 12 Immediately Increased Pre/Post p> 0.05  





60 s at 90% of 
max wattage 
followed by 
60 s at 50 W 
ug/L 10 Immediately Increased Pre/Post p< 0.05  
Townsend et al. 
(2015) 
1 Resistance 




squat at 80% 




ng/mL 10 Immediately Increased Pre/Post p> 0.05 Placebo group 
Tsuchiya et al. 
(2014) 
2 Resistance 
60 s max 
eccentric 
contractions 
Not reported 9 Immediately Increased Pre/Post p< 0.05  
Tsuchiya et al. 
(2014) 
2 Resistance 
30 s max 
eccentric 
contractions 
Not reported 8 Immediately Increased Pre/Post p> 0.05  





ng/mL 16 Immediately Increased Pre/Post p< 0.05 






from 260.08 to 
337.84 ng/mL 








ng/mL 10 Immediately Increased Pre/Post p> 0.05 
Male sedentary. 
Increased from 
218.16 to 238.79 
ng/mL  
Wahl et al. 
(2010) 
1 Sprint 
2 x 30 s max 
effort on cycle 
ergometer 
separated by 
5 min rest 
Not reported 11 Immediately No change Pre/Post p> 0.05  





for 1 h at 50% 
VO2max 
Not reported 11 Immediately No change Pre/Post p> 0.05  
West et al. 
(2013) 
2 Resistance 




on biodex at 
75% 1 RM, 5 
sets of 10 
reps bilateral 
leg press at 
95% 10 RM, 3 
sets of 12 






mmol/L 7 Immediately Increased Pre/Post p< 0.05  
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West et al. 
(2013) 
2 Resistance 
5 sets of 10 
reps bilateral 
leg press at 
95% 10 RM, 3 
sets of 12 






followed by 4 




on biodex at 
75% 1 RM  
mmol/L 7 Immediately Increased Pre/Post p< 0.05  
West et al. 
(2009) 
2 Resistance 
Arm curls 4 
sets of 8-12 
reps at 95% 
10 RM 
nM 8 Immediately Increased Pre/Post p> 0.05  
West et al. 
(2009) 
2 Resistance 
Arm curls 4 
sets of 8-12 
reps at 10 RM 
& 
immediately 
5 sets of 10 
reps & 3 sets 
of 12 reps leg 
extension/leg 
curl supersets 
at 90% 10 RM 
nM 8 Immediately Increased Pre/Post p> 0.05  






nM 10 Immediately Increased Pre/Post p> 0.05  
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leg press at 
80-90% 1 RM 








rest 3-5 min, 
5 sets of 5 
reps at 80% 1 
RM with 5 
min rest 
between sets  
ng/mL 8 
2 min after 
exercise 










min warm up, 
increased 
load by 15 W 















min warm up, 
increased 
load by 15 W 






nmol/L 10 Immediately Increased Pre/Post p< 0.01 







*Study design: pre/post= comparisons made between IGF-1 measurements before and after exercise; control= comparisons made between IGF-1 
measurements taken after exercise and at the same time point in a non-exercising control group  
**Exercise type: Sprint exercise includes exercise lasting 1 h or less and not resistance nor blood flow restriction exercise.  Endurance exercise includes 







min warm up, 
increased 
load by 15 W 
















min warm up, 
increased 
load by 15 W 






nmol/L 10 Immediately Increased Pre/Post p> 0.05 
Control group of 
age-matched 
healthy, not 
specifically trained 
men 
 
 
 
 
 
 
 
